

# Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia

Mishal Qubad  and Robert A. Bittner 

*Ther Adv Psychopharmacol*

2023, Vol. 13: 1–36

DOI: 10.1177/  
20451253231158152

© The Author(s), 2023.  
Article reuse guidelines:  
[sagepub.com/journals-](https://sagepub.com/journals-permissions)  
permissions

**Abstract:** Despite its enduring relevance as the single most effective and important evidence-based treatment for schizophrenia, underutilization of clozapine remains considerable. To a substantial degree, this is attributable to a reluctance of psychiatrists to offer clozapine due to its relatively large side-effect burden and the complexity of its use. This underscores the necessity for continued education regarding both the vital nature and the intricacies of clozapine treatment. This narrative review summarizes all clinically relevant areas of evidence, which support clozapine's wide-ranging superior efficacy – for treatment-resistant schizophrenia (TRS) and beyond – and make its safe use eminently feasible. Converging evidence indicates that TRS constitutes a distinct albeit heterogeneous subgroup of schizophrenias primarily responsive to clozapine. Most importantly, the predominantly early onset of treatment resistance and the considerable decline in response rates associated with its delayed initiation make clozapine an essential treatment option throughout the course of illness, beginning with the first psychotic episode. To maximize patients' benefits, systematic early recognition efforts based on stringent use of TRS criteria, a timely offer of clozapine, thorough side-effect screening and management as well as consistent use of therapeutic drug monitoring and established augmentation strategies for suboptimal responders are crucial. To minimize permanent all-cause discontinuation, re-challenges after neutropenia or myocarditis should be considered. Owing to clozapine's unique efficacy, comorbid conditions including substance use and most somatic disorders should not dissuade but rather encourage clinicians to consider clozapine. Moreover, treatment decisions need to be informed by the late onset of clozapine's full effects, which for reduced suicidality and mortality rates may not even be readily apparent. Overall, the singular extent of its efficacy combined with the high level of patient satisfaction continues to distinguish clozapine from all other available antipsychotics.

**Keywords:** antipsychotics, clozapine, mortality, re-challenge, schizophrenia, treatment resistance

Received: 16 November 2022; revised manuscript accepted: 24 January 2023.

## Introduction

With a life-time prevalence of 4.8–7.2 per 1000,<sup>1,2</sup> schizophrenia is one of the most common mental disorders with a high number of disability-adjusted life years.<sup>3</sup> Roughly two-thirds of all patients suffer from a recurrent or chronic course of illness,<sup>4</sup> and about 30% of all patients develop resistance against standard antipsychotic treatment.<sup>5–7</sup>

More than 65 years after its discovery and more than 30 years after the seminal study by Kane and colleagues,<sup>8</sup> clozapine remains the only effective antipsychotic drug for patients with treatment-resistant schizophrenia (TRS).<sup>9–12</sup> Moreover, the superior efficacy of clozapine for crucial clinical aspects of schizophrenia beyond narrowly defined treatment resistance is very well established.<sup>13–15</sup> Although these findings are reflected in all major

Correspondence to:  
**Robert A. Bittner**  
Department of Psychiatry,  
Psychosomatic Medicine  
and Psychotherapy,  
University Hospital  
Frankfurt, Goethe  
University, Heinrich-  
Hoffmann-Str. 10, D-60528  
Frankfurt am Main,  
Germany.

Ernst Strüngmann  
Institute (ESI) for  
Neuroscience in  
Cooperation with Max  
Planck Society, Frankfurt  
am Main, Germany  
[robert.bittner@med.uni-frankfurt.de](mailto:robert.bittner@med.uni-frankfurt.de)

**Mishal Qubad**  
Department of Psychiatry,  
Psychosomatic Medicine  
and Psychotherapy,  
University Hospital  
Frankfurt, Goethe  
University, Frankfurt am  
Main, Germany

national and international treatment guidelines,<sup>16–20</sup> converging evidence from developed countries clearly indicates that clozapine remains substantially underused.<sup>21</sup> It has been suggested that one major reason for this situation is a lack of sufficient training and experience regarding clozapine treatment in a considerable number of psychiatrists.<sup>22,23</sup> While specific prescriber-related obstacles remain rather poorly understood,<sup>22</sup> they may include a delayed detection of TRS, incomplete knowledge of clozapine's broad beneficial effects, and an unfounded hesitance to use or maintain clozapine in accordance with guideline recommendations out of respect for its potential side-effects.<sup>24</sup>

Here, we review the current literature on all clinically relevant aspects of clozapine treatment with a particular emphasis on those we deem most pertinent to help rectify these issues. This includes guidance for optimal side-effect monitoring and management geared toward maximizing the number of patients, who can be treated safely with clozapine, while minimizing the overall number of treatment discontinuations. Moreover, by highlighting the current evidence for the full range of its clinical effects, we want to encourage increased use of clozapine not only in TRS but also in other patient groups, for which this unique medication can provide unmatched benefits.

### Literature selection

We based our review on a MEDLINE and Google Scholar search for all relevant topics, selecting both relevant individual clinical studies as well as meta-analyses and reviews. We included all articles that were published until November 2022. We searched for publications containing the following MeSH terms: treatment-resistant schizophrenia [AND] criteria, treatment-resistant schizophrenia [AND] treatment, treatment-resistant schizophrenia [AND] neurobiology, clozapine [AND] *xx*, with *xx* reflecting the topic we aimed to focus at that time-point (e.g. side-effects, neutropenia, agranulocytosis, hypersalivation, pneumonia, myocarditis, re-challenge, re-challenge [AND] myocarditis, re-challenge [AND] neutropenia, withdrawal, discontinuation, pregnancy, breastfeeding elderly, metabolic syndrome, gastrointestinal side effects, sedation, mortality, pharmacokinetics, pharmacodynamics, valproate, clinical effects, clozapine-resistant schizophrenia). In addition, we manually screened reference lists of topical review articles. In cases in which we did not have any access to the full article, we contacted the study authors. Literature


selection was also informed by our own clinical experience in the use of clozapine.

### Treatment-resistant schizophrenia

The international guidelines by the Treatment Response and Resistance in Psychosis (TRRIP) Working Group provide a clear consensus definition of TRS.<sup>25</sup> A central criterion is the presence of persistent symptoms of at least moderate severity despite adequate standard antipsychotic treatment.<sup>25</sup> Importantly, persistent symptoms do not need to cause subjective distress in patients but must have some degree of objectifiable detrimental functional impact. Moreover, pseudo-resistance due to continued use of hallucinogenic drugs or insufficient antipsychotic plasma levels needs to be excluded.<sup>25,26</sup> Pseudo-resistance can also result from side-effects or comorbid medical conditions masking the clinical effects of antipsychotic treatment.<sup>13,25</sup> In this context, the importance of therapeutic drug monitoring is underscored by evidence from a naturalistic clinical setting indicating that approximately 30% of patients with suspected treatment resistance should in fact be classified as 'pseudo-resistant' because of subtherapeutic antipsychotic plasma levels.<sup>27–29</sup> Finally, a comprehensive diagnostic workup is essential to rule out other underlying disorders.

The minimal criteria for TRS encompass the following points:

1. Persistent symptoms (positive, negative, and cognitive symptoms) over at least three months of at least moderate severity causing at least moderate functional impairments. Symptoms classification and thresholds require the use of standardized, validated clinical rating scales.
2. Insufficient response to treatment with at least two different antipsychotic drugs with a minimum duration of treatment of twelve weeks (six weeks for each drug). This corresponds to a minimum chlorpromazine dose equivalent of 600 mg per day.
3. Ascertainment of sufficient treatment adherence defined as patients having taken at least 80% of the prescribed doses. To this end, at least two of the following methods need to be employed: counting pills, patient and caregiver report, and chart and record reviews. In addition, blood plasma drug levels should be monitored at least once for each antipsychotic.



**Figure 1.** Treatment-resistant schizophrenia.

Minimal criteria for the diagnosis of treatment resistance according to current TRIPP guidelines.<sup>25</sup>  
Created with BioRender.com.

In addition to these minimal TRS criteria (Figure 1), which are most relevant for clinical practice, optimal criteria have been proposed, which are geared more toward use in clinical trials.<sup>25</sup>

### The neurobiology of treatment resistance

Importantly, in 70–80% of cases, treatment resistance emerges already during the first psychotic episode, highlighting the need for an early detection of this condition.<sup>5,6,30,31</sup> Several risk factors for the development of TRS have been identified. These include male sex, living in a less urban area, younger age, family history of psychosis, a high load of schizophrenia risk genes, longer duration of untreated psychosis, substance abuse, and a higher number of relapses due to non-adherence.<sup>4,32–34</sup> Obstetric complications, lower premorbid social adjustment, a history of suicide attempts, extended hospitalization, impaired illness insight, and comorbid personality disorders have also been associated with an increased risk for TRS.<sup>32,34–36</sup>

The exact neurobiological underpinnings of TRS remain elusive. Some authors distinguish between primary and secondary TRS.<sup>7,37–40</sup> While primary TRS is present at illness onset, secondary TRS manifests during later stages of the disorder after an initially sufficient response to antipsychotic treatment.<sup>7,39,40</sup> Dopaminergic supersensitivity has been discussed as one likely cause of secondary TRS.<sup>7,41</sup> Upregulation of striatal postsynaptic dopamine D2 receptors in response to antipsychotic treatment can lead to psychotic exacerbation despite continuous

treatment. Consecutive dose increases of antipsychotics can induce further receptor upregulation inducing dopaminergic supersensitivity. In general, serotonin dysregulation and inflammation as well oxidative stress have been proposed to be involved in the pathophysiology of TRS.<sup>7</sup> There is also converging evidence that abnormalities in glutamatergic neurotransmission might contribute to the emergence of treatment resistance,<sup>41</sup> which would also be compatible with the existence of a normodopaminergic subtype of schizophrenia.<sup>7,37,38</sup> A higher genetic load for schizophrenia also appears to increase the risk for TRS.<sup>7,33,42,43</sup>

### Clinical effects of clozapine

Unequivocal evidence supports the superior efficacy of clozapine for the reduction of positive symptoms and global psychopathology in TRS compared with other antipsychotics.<sup>8,12,44–46</sup> Patients treated with clozapine also show improved treatment adherence<sup>11</sup> and reduced rehospitalization rates.<sup>47–52</sup> It is crucial to emphasize that there is no evidence for a comparable efficacy of antipsychotic polypharmacy, that is, the combination of two non-clozapine antipsychotics.<sup>16</sup> Therefore, offering clozapine should always take precedence when treating patients with TRS.

Importantly, the beneficial effects of clozapine go far beyond positive symptoms. Clozapine is among the most effective antipsychotics for improving negative symptoms.<sup>14,46,53</sup> It also shows a similar level of efficacy against depressive symptoms,<sup>14</sup>

which constitute a common, independent risk factor for suicidality in schizophrenia.<sup>54</sup> Accordingly, clozapine leads to a stronger reduction of both suicidal behavior<sup>55–57</sup> and suicide mortality compared with other antipsychotics.<sup>15</sup> Some guidelines therefore explicitly recommend clozapine for persistent suicidality independent of treatment resistance.<sup>16–20</sup> Compared with other antipsychotics, clozapine also shows superior efficacy in reducing aggressive and violent behavior.<sup>58–62</sup> Furthermore, clozapine lowers the risk of developing a substance use disorder (SUD),<sup>52</sup> and also reduces relapse rates in patients with a comorbid SUD.<sup>52,63</sup>

Response rates to antipsychotic treatment in drug-naïve patients are estimated at 75%.<sup>64,65</sup> Conversely, response rates to a second trial with a standard antipsychotics are considerably lower, ranging between 20% and 45%.<sup>64,65</sup> Estimates for overall response rates range between 40% and 60%.<sup>66,67</sup> Clinical efficacy of clozapine depends crucially on early treatment initiation.<sup>66,68–70</sup> Response rates for treatment initiation within the first 2–3 years after establishing treatment resistance can reach up to 80%.<sup>64,66,71</sup> For later treatment initiation, response rates can be as low as 30%.<sup>66</sup> Combined with the clear evidence for a predominantly early onset of treatment resistance, these findings underscore the vital importance of offering and starting clozapine early.

### Pharmacodynamics

Clozapine is an antagonist at all dopamine-receptor subtypes (D1–D5).<sup>72</sup> Among them, the antipsychotic effects of clozapine appear to be primarily mediated *via* D2 receptor antagonism.<sup>73</sup> In this regard, clozapine mirrors other antipsychotics, but its superior efficacy for positive symptoms appears to be the result of additional pharmacological properties. Even after decades of clinical use, the neurobiological mechanisms underlying the broad superior clinical efficacy of clozapine remain elusive. Currently, effects in the glutamatergic<sup>74–77</sup> as well as the GABAergic system are discussed as likely explanations.<sup>78–80</sup> The pleiotropic effects of clozapine, however, also encompass neurobiological systems not directly related to neurotransmission,<sup>37,75,81–83</sup> but their relevance remains unclear.

By comparison, the properties underlying clozapine's side-effect profile are relatively well established. The nearly complete absence of extrapyramidal symptoms is most likely attributable to rapid dissociation of

clozapine from striatal D2-receptors.<sup>84</sup> Antagonism at serotonergic 5HT<sub>2C</sub>- and 5HT<sub>2A</sub>-receptors<sup>85,86</sup> and at histaminergic H<sub>1</sub>-receptors is implicated in clozapine-associated weight gain.<sup>85</sup> Antagonism at H<sub>1</sub>-histaminergic receptors<sup>87,88</sup> as well as agonism at gamma-aminobutyric acid (GABA) B receptors have been implicated in sedation.<sup>80</sup> Serotonergic antagonism appears to be involved in clozapine-associated obsessive compulsive symptoms.<sup>89,90</sup> Clozapine's unique muscarinic profile is responsible for several highly relevant side effects. Agonistic effects at M<sub>4</sub>-receptors are the primary cause of hypersalivation. Conversely, antagonism at M<sub>2</sub>-receptors is implicated in clozapine-induced gastrointestinal hypomotility (CIGH). Anticholinergic mechanisms might also worsen symptoms associated with cognitive decline, cause delirium, and urinary retention.<sup>91</sup> In addition, clozapine's antagonistic properties at adrenergic receptors have been linked to nocturnal enuresis, hypotension, and hypersalivation.<sup>92,93</sup>

### Pharmacokinetics and interactions

Clozapine's half-life is approximately 14 h.<sup>94,95</sup> Its metabolism is influenced by several factors including hormones like estrogens, concurrent medication, smoking,<sup>96</sup> sex, with higher blood plasma levels in females,<sup>97,98</sup> and age.<sup>96,99–102</sup> Ethnicity can also have an effect, with people of Asian descent generally reaching sufficient clozapine plasma levels at lower doses than Caucasians.<sup>100</sup>

The following cytochrome P450 (CYP)-enzymes are mainly involved in clozapine metabolism: CYP1A2 (30%), CYP2C19 (24%), CYP3A4 (22%), CYP2C9 (12%), and CYP2D6 (6%).<sup>103</sup> Among them, CYP1A2 induction or inhibition can lead to clinically relevant changes in plasma clozapine levels.<sup>94,95</sup> Inhibitors include caffeine,<sup>104</sup> and C-reactive protein (CRP),<sup>105–107</sup> which can be triggered by infections. This is underscored by recent reports of toxic plasma clozapine levels during SARS-CoV-2 infections.<sup>108,109</sup> Oral contraceptives containing estrogens also inhibit CYP1A2 and CYP2C19 enzyme activity leading to clinically relevant plasma level increases.<sup>110,111</sup> Polycyclic aromatic hydrocarbons (PAHs) contained in cigarette smoke are the most relevant CYP1A2 inducers.<sup>112,113</sup> Importantly, after abrupt smoking cessation, enzyme activity typically normalizes within three days,<sup>112</sup> which can lead to toxic plasma clozapine levels.<sup>113–121</sup> Notably, nicotine patches and e-cigarettes are not associated with a comparable interaction risk.<sup>28,122–125</sup>

Optimal plasma clozapine levels for the treatment of TRS fall in the range of 350–600 µg/L.<sup>126,127</sup> Plasma clozapine levels above 600 µg/L increase the risk for side-effects considerably.<sup>128</sup> Plasma clozapine levels above 1000 µg/L are considered toxic, are associated with an at least two-fold increase in mortality risk,<sup>129</sup> and require immediate dose reduction and intensified pharmacovigilance. Plasma clozapine levels above 2000 µg/L are acutely life-threatening.<sup>130,131</sup> Notably, clozapine intoxication is associated with a delayed plasma peak due to clozapine's extensive entero-hepatic circulation and its induction of gastrointestinal hypomotility.<sup>132</sup> In general, international guidelines strongly recommend regular monitoring of plasma clozapine levels to increase both patient safety and response rates.<sup>28,29</sup>

In rare cases, rapid metabolism of clozapine due to yet unknown causes may preclude reaching sufficient plasma clozapine levels.<sup>133–135</sup> Here, augmentation with low doses of fluvoxamine, a strong CYP1A2 inhibitor, should be considered.<sup>136–138</sup> A total of 25–50 mg of fluvoxamine can raise plasma clozapine levels five- to ten-fold within 2–4 weeks<sup>139–141</sup> and also triple clozapine's half-life.<sup>142</sup> Consequently, frequent screening for side effects and therapeutic drug monitoring are crucial during augmentation with fluvoxamine.<sup>28,29</sup>

In summary, there are several relevant pharmacokinetic and pharmacodynamic interactions clinicians need to be aware of (Tables 1 and 2). When addressing such interactions, switching to safer alternatives for interacting drugs wherever possible should be the primary strategy. Discontinuation of clozapine should only be considered as a last resort.

### Clozapine metabolites

Clozapine is mainly demethylated to *n*-desmethyl-clozapine (norclozapine) and oxidized to clozapine-*n*-oxide.<sup>95</sup> In contrast to clozapine-*n*-oxide, norclozapine is pharmacologically active. Compared with clozapine, norclozapine shows diverging effects on dopaminergic and muscarinic receptors<sup>98,160</sup> and also affects serotonergic receptors among others.<sup>161–164</sup> While it has no antipsychotic properties, norclozapine appears to contribute to the overall side-effect burden including sedation, hypersalivation, constipation, metabolic complications, and seizures.<sup>163</sup>


**Table 1.** Pharmacokinetic interactions.

CYP inducers	CYP inhibitors
Omeprazole <sup>143</sup>	Selective serotonin re-uptake inhibitors (SSRIs; e.g. fluvoxamine und fluoxetine; sertraline in high doses) <sup>104,143</sup>
Carbamazepine <sup>128,144</sup>	Quinolone antibiotics (e.g. ciprofloxacin) <sup>104,143</sup>
St. John's wort <sup>128</sup>	Macrolide antibiotics (e.g. erythromycin) <sup>143</sup>
PAH <sup>143</sup>	Caffeine <sup>104</sup>
	Ethinyl estradiol <sup>104,143</sup>
	Propranolol <sup>145</sup>
CYP, cytochrome P450; PAH, polycyclic aromatic hydrocarbon.	

**Table 2.** Pharmacodynamic interactions.

Side-effects	Most relevant medications
Hypotension	Tricyclic antidepressants (TCA), antihypertensive medication (e.g. propranolol, ACE inhibitor) <sup>73,146</sup>
Sedation	Benzodiazepines <sup>73</sup>
Anticholinergic gastrointestinal side-effects	TCA, anticholinergic drugs <sup>73,92,147</sup>
Other anticholinergic side-effects (e.g. delirium)	TCA, anticholinergic drugs, opioids, antihistaminergic drugs <sup>73,92,94,147</sup>
Hematological side-effects	Carbamazepine, metamizole, TCA, mirtazapine, bupropion, valproate, carbamazepine, cytostatic drugs, chloramphenicol, sulfonamide, co-trimoxazole <sup>73,94,148–150</sup>
Reduction of seizure threshold	Bupropion, lithium, TCA <sup>73,94,151–153</sup>
QT prolongation	Macrolide antibiotics (e.g. erythromycin), quinolone antibiotics (e.g. moxifloxacin), TCA <sup>73,154–156</sup>
Myocarditis	Valproate <sup>94,157–159</sup>
ACE, angiotensin-converting enzyme.	

Recently, the clozapine:norclozapine ratio has received growing attention.<sup>98,136,165</sup> Based on clinical observations, the optimal clozapine: norclozapine ratio is deemed to be around two. Higher values are indicative of a non-trough blood



**Figure 2.** Clozapine-associated side effects.

Overview of the clinically most relevant side effects encountered in patients receiving clozapine.

Adapted from "Human Internal Organs", by BioRender.com (2022). Retrieved from <https://app.biorender.com/biorender-templates> [accessed on 16th November 2022].

sample, a recently missed dose, or decreased CYP1A2 enzyme activity. Lower values appear to be indicative of increased CYP1A2 enzyme activity.<sup>136,165,166</sup> Other authors, however, recommend using the total clozapine C/D ratio, with C representing the sum of the clozapine and norclozapine trough steady-state plasma concentration and D representing the daily dose of clozapine.<sup>98</sup>

### Side effects of clozapine

Owing to the relatively high side-effect burden associated with clozapine (Figure 2 and Table 3), extensive pharmacovigilance as well as early and consistent management of side-effects are of particular importance.<sup>167</sup> Frequent consultation of both patients and their families is an important element of this strategy.<sup>101</sup> In addition to clozapine's

**Table 3.** Management of clozapine-associated side effects.

Side-effect	Monitoring and diagnostics	Prevention and management
Metabolic syndrome* (obesity, hypertension, dyslipidemia, diabetes) <sup>168–170</sup>	<ul style="list-style-type: none"> <li>Baseline-screening: weight/BMI, lipid profile, HbA1c               <ul style="list-style-type: none"> <li>BMI/weight: monthly 1st/2nd/3rd/6th month, then yearly<sup>171–173</sup></li> <li>Lipid profile: quarterly<sup>174,175</sup></li> <li>Diabetes screening: quarterly<sup>94</sup></li> </ul> </li> </ul>	<p>Non-pharmacological treatment:</p> <ul style="list-style-type: none"> <li>Lifestyle changes, psychotherapy<sup>176,177</sup></li> </ul> <p>Pharmacological treatment:</p> <ul style="list-style-type: none"> <li>Obesity/weight gain: as early as possible; mandatory in cases of weight gain of <math>\geq 7\%</math> and in cases with BMI <math>\geq 25</math>:               <ul style="list-style-type: none"> <li>Metformin<sup>13,16,178,179</sup> <ul style="list-style-type: none"> <li>contraindication for metformin: eGFR of <math>&lt;30</math> ml/min</li> <li>frequent monitoring of vitamin B<sub>12</sub> level<sup>177</sup></li> </ul> </li> <li>Alternative options: GLP1-receptor agonists,<sup>180</sup> topiramate<sup>181–184</sup></li> </ul> </li> <li>Hypertension: antihypertensive drugs<sup>176,185,186</sup></li> <li>Dyslipidemia: statins<sup>176</sup></li> </ul>
Hypersalivation (increases risk for pneumonia) <sup>187–191</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment using standardized rating scales, for example, the <i>Drooling severity scale</i> or <i>Nocturnal Hypersalivation Rating Scale</i><sup>192,193</sup></li> </ul>	<ul style="list-style-type: none"> <li>Sugar free chewing gum during the day to promote saliva swallowing; elevation of upper body during the night<sup>193</sup></li> <li>Pirenzepine (25–100 mg/d); Cave: anticholinergic load<sup>16,94,191</sup></li> <li>Alternative options: atropine drops s.l., ipratropium bromide s.l.<sup>191</sup></li> <li>Botulinumtoxin injection (incobotulinum toxin A) into the parotid and submandibular glands<sup>16,189,194–198</sup></li> </ul>
Sinus tachycardia <sup>199,200</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment including ECG<sup>126</sup></li> <li>Diagnostics: 12 channel ECG, 24-h Holter monitoring; consider stress ECG, TTE, laboratory tests according to established guidelines<sup>201,202</sup></li> </ul>	<ul style="list-style-type: none"> <li>Treatment with ivabradine (no depressogenic effects reported) or cardio-selective beta blockers (Cave: hypotension, bronchospasm, depressogenic)<sup>16,94,199,203,204</sup></li> </ul>
Constipation, CIGH* <sup>205,206</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment<sup>94,101,167</sup></li> </ul>	<ul style="list-style-type: none"> <li>Physical activity, sufficient fluid intake, fiber-rich diet<sup>16,94,207,208</sup></li> <li>Discontinue non-essential drugs that increase anticholinergic load<sup>209,210</sup></li> <li>Treatment with laxatives<sup>207,208,211</sup></li> </ul>
Hematological side-effects <sup>212,213</sup>	<ul style="list-style-type: none"> <li>Complete differential blood count: at baseline, once weekly (1st–18th week), then monthly; in case of discontinuation continue monitoring for 4 weeks<sup>73,94,214</sup></li> <li>Leukopenia (white blood cells [WBCs] <math>&lt;4</math>/nl) versus CIN (ANC <math>&lt;1.5</math>/nl) versus CIA (ANC <math>&lt;0.5</math>/nl)<sup>73,214–216</sup> <ul style="list-style-type: none"> <li>In cases of WBC 3–3.5/nl and ANC 1.5–2/nl: Monitoring twice per week<sup>94,217–221</sup></li> </ul> </li> <li>Eosinophilia <math>&gt;3</math>/nl: search for CIM, pancreatitis, DRESS syndrome, CIA</li> <li>BEN: does not constitute a contraindication; consider expanding monitoring<sup>221–225</sup></li> <li>Most hematological changes are only transient<sup>226</sup></li> </ul>	<ul style="list-style-type: none"> <li>Confirmed CIA (ANC <math>&lt;0.5</math>/nl): discontinue clozapine, infection prevention, consider administration of G-CSF/GM-CSF<sup>16,217–221</sup></li> <li>Thrombocytopenia <math>&lt;50</math>/nl: discontinue clozapine temporarily<sup>227,228</sup></li> <li>Eosinophilia <math>&gt;3</math>/nl: discontinue clozapine temporarily; do not restart clozapine unless eosinophil count <math>&lt;1</math>/nl<sup>73,94,217,229–233</sup></li> </ul>
Sedation* <sup>88,190,234</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment</li> <li>Most commonly transient in nature<sup>88,190,234</sup></li> </ul>	<ul style="list-style-type: none"> <li>Titration to lowest effective dose<sup>16,190,234</sup></li> <li>Minimize daytime doses<sup>190,234</sup></li> <li>Avoid concomitant sedating drugs<sup>94,190,234</sup></li> </ul>

(Continued)

**Table 3.** (Continued)

Side-effect	Monitoring and diagnostics	Prevention and management
Myocarditis, cardiomyopathy <sup>235,236</sup>	<ul style="list-style-type: none"> <li>Highest risk during the first 4 weeks of treatment</li> <li>Risk factors: rapid dose titration (&gt;25 mg/d), higher age, concomitant valproate<sup>237</sup></li> <li>Mandatory clinical, electrophysiological, and laboratory monitoring at baseline and during the first 8 weeks of treatment: heart rate; ECG; TTE (if available); CRP, troponin, CK, BNP, full blood count<sup>94,238,239</sup></li> <li>Clinical signs: cardiac symptoms/gastrointestinal and urogenital disturbances including non-specific flu-like symptoms, dyspnea, diarrhea, fever; increased heart rate by <math>\geq 20</math>–30/min, signs of reduced left ventricular function<sup>94,239</sup></li> <li>Cardiac monitoring signs: unspecific changes in ECG; TTE: changes in pericardial effusion, cardiac wall motion abnormalities<sup>240</sup></li> <li>Laboratory signs: CRP, troponin, CK, BNP: <math>\uparrow</math>, eosinophilia (delayed)<sup>94,239,241</sup></li> </ul>	<ul style="list-style-type: none"> <li>Mandatory discontinuation of clozapine in case of CRP level increases of more than 10<math>\times</math> upper limit normal (ULN) or troponin level increases of more than 2<math>\times</math> ULN<sup>212,235,236,242</sup></li> <li>Cardioprotective treatment: ACE-inhibitors and beta blockers<sup>243</sup></li> <li>In severe cases, transfer to intensive care unit<sup>94,244</sup></li> <li>Symptoms improve within 5 days of treatment termination; most common course: <i>restitutio ad integrum</i>,<sup>94,242</sup> cardiomyopathy is a potential complication</li> </ul>
QT prolongation <sup>*141,154–156</sup>	<ul style="list-style-type: none"> <li>Frequent ECGs: weekly for the 1st month, afterwards at least quarterly<sup>94,141,154–156,245</sup></li> <li>Use corrected QT-time with appropriate formula (e.g. <i>Fridericia</i>)<sup>141</sup></li> </ul>	<ul style="list-style-type: none"> <li>Avoid concomitant drugs causing QT prolongation whenever possible<sup>141,246</sup></li> <li>Slow dose titration<sup>141,246</sup></li> <li>Avoid hypokalemia and hypomagnesemia<sup>245,247</sup></li> <li>Consider oral supplementation of magnesium<sup>141</sup></li> <li>Search for signs of CIM<sup>141</sup></li> </ul>
Seizures <sup>*163,248–250</sup>	<ul style="list-style-type: none"> <li>EEG: at baseline, after 3 months, afterwards every 6 months<sup>94</sup></li> <li>Risk factors: higher doses, rapid dose titration, history of seizures or head trauma, concomitant medication or compounds resulting in pharmacodynamic or pharmacokinetic changes (e.g. lithium, smoking cessation), physical illness (e.g. hyponatremia), substance abuse<sup>73,94,104,162,249</sup></li> <li>Pre-existing and sufficiently medically controlled epilepsy does not constitute a contraindication<sup>94,250</sup></li> </ul>	<ul style="list-style-type: none"> <li>Consider clozapine dose reduction by about 50%</li> <li>Combine with anticonvulsant medication: lacosamide (Cave: neutropenia), gabapentine, lamotrigine;<sup>94,151,249–251</sup> avoid valproate (risk factor for CIM)</li> </ul>
Obsessive compulsive symptoms <sup>252,253</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment</li> <li>Largely independent of dose and treatment duration<sup>89</sup></li> </ul>	<ul style="list-style-type: none"> <li>Clozapine dose reduction</li> <li>CBT, SSRI, consider combination with aripiprazole<sup>89,94</sup></li> </ul>
Akathisia <sup>*94,254–256</sup>	<ul style="list-style-type: none"> <li>Regular clinical assessment</li> <li>Cave: can be present without overt motor signs<sup>257</sup></li> </ul>	<ul style="list-style-type: none"> <li>Dose reduction<sup>92,258,259</sup></li> <li>Propranolol (30–120 mg) – Cave: drug–drug interaction <i>via</i> CYP450-enzymes<sup>145,255,260</sup></li> <li>Mirtazapine (7.5–15 mg)<sup>255,260</sup></li> </ul>

(Continued)

**Table 3.** (Continued)

Side-effect	Monitoring and diagnostics	Prevention and management
Pneumonia <sup>261</sup>	<ul style="list-style-type: none"> <li>Risk factor: hypersalivation, sedation, older age, male sex, concomitant medication (e.g. <i>via</i> promoting sedation)<sup>261–263</sup></li> </ul>	<ul style="list-style-type: none"> <li>Prevention: early treatment of hypersalivation<sup>153,264,265</sup></li> <li>In case of pneumonia: adjust clozapine dose, increase frequency of monitoring and consider increased risk for interactions associated with CYP450 enzymes (e.g. CRP, antibiotics)<sup>94,266</sup></li> <li>Ensure sufficient respiratory disease vaccination status (influenza and SARS-CoV2)</li> </ul>
Other clinically relevant side effects: hepatitis, nephritis, pancreatitis, <sup>267,268</sup> delirium*, enuresis, NMS, <sup>93,94,167,269,270,271</sup> DRESS syndrome, <sup>230,272</sup> venous thromboembolism, <sup>212,273</sup> diabetic ketoacidosis, hyperosmolar coma <sup>212,274</sup>	<ul style="list-style-type: none"> <li>Clinical assessment, laboratory parameter<sup>275</sup></li> <li>Cave: delirium associated with high clozapine doses and with abrupt clozapine discontinuation<sup>275,276</sup></li> <li>NMS: rare (clozapine is the drug of first choice after NMS)<sup>269,271,277</sup></li> <li>Pancreatitis: screen for signs of exocrine and endocrine pancreas insufficiency</li> <li>DRESS syndrome: assess laboratory parameters frequently (especially eosinophils, lymphocytes);<sup>230,272</sup> risk factor: combination with lithium, anticonvulsants (including valproate)</li> </ul>	<ul style="list-style-type: none"> <li>Enuresis: avoid late fluid intake, continence training, desmopressin<sup>94,270,278</sup></li> <li>Hepatitis, pancreatitis, nephritis: rare; discontinue clozapine, initiate specific treatment<sup>94,268,279</sup></li> <li>Delirium: pause clozapine,<sup>73,275,280</sup> treat delirium<sup>94</sup></li> <li>DRESS syndrome: discontinue clozapine; initiate symptomatic treatment (e.g. antipyretic, antihistaminergic, immunosuppression with steroid/intravenous immunoglobulins)<sup>230,272</sup></li> </ul>

ACE, angiotensin-converting enzyme; ANC, absolute neutrophil count; BEN, benign ethnic neutropenia; BMI, body mass index; BNP, brain natriuretic peptide; CBT, cognitive behavioral therapy; CIA, clozapine-induced agranulocytosis; CIGH, clozapine-induced gastrointestinal hypomotility; CIM, clozapine-induced myocarditis; CIN, clozapine-induced neutropenia; CK, creatine kinase; CRP, C-reactive protein; CYP, cytochrome P450; DRESS, drug reaction with eosinophilia and systemic symptom; ECG, electrocardiography; EEG, electroencephalography; G-CSF, granulocyte colony-stimulating factor; GLP1, glucagon-like peptide-1; GM-CSF, granulocyte-macrophage colony-stimulating factor; NMS, neuroleptic malignant syndrome; SSRI, selective serotonin re-uptake inhibitor; TTE, transthoracic echocardiogram.

\*Dose-dependent side-effect.

broad antagonistic and agonistic effects on key neurotransmitter systems outlined above, immunomodulatory effects, which might partly explain clozapine's unique efficacy, have also been implicated in adverse drug reactions (ADRs) including eosinophilia, myocarditis, pancreatitis, and nephritis.<sup>167</sup> Side-effect risk decreases with slower initial dose titration regimes.<sup>101</sup> This is particularly important in light of evidence for an association between rapid initial dose escalation and risk for both myocarditis and neutropenia.<sup>92</sup> Owing to the clear dose dependency of some side effects (Table 3), dose reductions should be attempted first whenever feasible before considering other options.<sup>101</sup>

#### *Hematological side effects*

Not least for historic reasons,<sup>281</sup> clozapine is closely associated with agranulocytosis and other, less serious forms of neutropenia. An absolute

neutrophil count (ANC) of 1–1.5/nl is referred to as mild neutropenia while ANCs of 0.5–1.0/nl are referred to as moderate neutropenia. ANCs of <0.5/nl constitute severe neutropenia.<sup>282</sup> ANCs below 0.5/nl are also typically referred to as agranulocytosis.<sup>215,283,284</sup> However, strictly speaking agranulocytosis requires near absence of neutrophils, that is, ANCs below 0.1/nl.<sup>283,285</sup> The clinical syndrome of agranulocytosis is commonly associated with a triad of symptoms encompassing fever, mouth ulcers, and sore throat.<sup>215</sup> Pragmatically equating severe neutropenia and agranulocytosis is motivated by the substantial risk for opportunistic infections associated with ANCs below 0.5/nl,<sup>215</sup> which triggers several clinical actions discussed in detail below. For pragmatic purposes, we will therefore likewise refer to ANCs of 1.5–0.5/nl as clozapine-induced neutropenia (CIN) and to ANCs of <0.5/nl as clozapine-induced agranulocytosis (CIA).

Owing to an increased risk for CIN and CIA, frequent blood cell counts are mandatory throughout treatment.<sup>212,281,286</sup> This procedure has reduced risk of death from CIA to less than 1 in 10,000 patients.<sup>238</sup> Risk for CIN and CIA is estimated to be 3% and 0.4–0.7%, respectively.<sup>217,287</sup> Although CIN or CIA can occur at any time during treatment,<sup>288,289</sup> the highest incidence rates have been observed during the first 6–18 weeks of treatment (49% cases of neutropenia, 82% cases of agranulocytosis) with a clear subsequent risk decrease after six months.<sup>73,213,217,287,290</sup> This should be considered when a comorbid somatic disorder necessitates treatment with a drug also linked to blood dyscrasia. Whenever possible, treatment with such drugs should be initiated after the critical first six months.<sup>213</sup>

Currently, safety thresholds for neutrophil counts during clozapine treatment vary slightly across health systems. Importantly, discontinuation should require clear evidence for a downward dynamic of the neutrophil count,<sup>219,220,291</sup> as cases of transient neutropenia under clozapine treatment have also been observed.<sup>292</sup> Moreover, an immediate thorough search for other causes of blood dyscrasia is essential, as this would have important implications for a potential re-challenge of clozapine.<sup>217,218,287</sup> Important causes include concomitant medication – including antibiotics<sup>273,293</sup> and psychotropic compounds like carbamazepine and valproate<sup>294,295</sup> – or viral infections.<sup>296</sup>

Confirmed CIN and CIA stipulate immediate discontinuation of clozapine. In addition, CIA requires the administration of granulocyte colony-stimulating factor (G-CSF). Moreover, further actions to prevent and treat infections, for example, administration of antibiotics and protective isolation, might be necessary.<sup>297–299</sup>

In cases of mild neutropenia even before treatment onset, benign ethnic neutropenia (BEN) is an important differential diagnosis, which does not constitute a contraindication.<sup>221–225</sup> Safety thresholds for patients with a confirmed diagnosis of BEN are lower (Figure 3(a) and Table 3).<sup>300</sup> Pseudo-neutropenia resulting from physiologically reduced neutrophil counts due to higher cortisol levels in the morning should also be considered.<sup>217</sup>


The pathophysiology of CIN and CIA remains poorly understood, but an autoimmune mechanism

appears most likely. Eosinophilia is another important but rare hematological side effect. Importantly, eosinophilia does not warrant permanent discontinuation of clozapine.<sup>212,301</sup> Treatment can be restarted at eosinophil counts below 1/nl. Eosinophilia, however, should prompt a search for other clozapine-induced ADRs including CIA, clozapine-induced myocarditis (CIM), pancreatitis, and drug reaction with eosinophilia and systemic symptom (DRESS) syndrome.<sup>227,302</sup>

Notably, a recent longitudinal study revealed an increased risk for hematological malignancies in patients receiving clozapine.<sup>303</sup> This risk, however, is smaller than the reduction of all-cause mortality associated with clozapine. Moreover, mortality rates in clozapine users diagnosed with a hematological malignancy were lower compared with patients treated with nonclozapine antipsychotics.<sup>303–305</sup> Therefore, while these findings necessitate increased vigilance regarding signs of hematological malignancy in clozapine users, they do not undermine the general case for clozapine.<sup>304,305</sup>

### Cardiac side effects

CIM is among the most important and yet underdiagnosed side effects. CIM risk is the highest during the first 4 weeks after treatment initiation,<sup>306,157</sup> but also during re-exposure following a first successful trial.<sup>94</sup> Moreover, rare cases of CIM after long-term treatment of more than a decade have also been observed.<sup>73,307,308</sup> Compared with CIN and CIA, the incidence of CIM is noticeably higher.<sup>157,309</sup> The timely detection of CIM might be impeded by its often unspecific clinical presentation, which can include flu-like symptoms like fever, dyspnea, myalgia, and vague complaints of fatigue and malaise.<sup>242,309,310</sup> Patients might also experience symptoms reflecting cardiac involvement such as chest pain, hypotension, palpitation, tachycardia, and peripheral edema.<sup>242,309,310</sup> These more specific symptoms, however, are by no means mandatory. By contrast, there have been reports of cases solely presenting with gastrointestinal and urogenital disturbances like diarrhea, dysuria, and vomiting.<sup>241,242,310,311</sup> Hence, frequent screening for clinical, electrophysiological, and laboratory signs of CIM is mandatory.<sup>94,147,167,241</sup> Electrocardiographic (ECG) findings in CIM are characterized by non-specific alterations such as T-wave inversion and ST elevation or



**Figure 3.** Screening and management of clozapine-induced neutropenia (CIN) and clozapine-induced myocarditis (CIM). (a) Color code categorization of CIN screening parameters and required action. Absolute neutrophil counts within the green range do not require any action except regular monitoring. ANC's within the yellow range require intensified full blood monitoring and searching for an alternative cause. ANC's within the red range necessitate immediate discontinuation of clozapine, daily monitoring of full blood count, and searching for an alternative cause. (b) Color code to categorization of CIM screening parameters and required action. Results within the green range do not require any action except regular monitoring. Results within the yellow range require intensified monitoring and searching for an alternative cause. Results within the red range necessitate immediate discontinuation of clozapine, daily monitoring, initiation of cardioprotective treatment, and searching for an alternative cause.

depression.<sup>242,312</sup> Transthoracic echocardiogram (TTE) might reveal left ventricular impairments and pericardial effusion, while cardiac magnetic resonance imaging (MRI) can provide more direct evidence for myocardial inflammation.<sup>240,313</sup> In addition, endomyocardial biopsy can be performed to rule out viral myocarditis.<sup>314</sup> Mandatory laboratory screening at baseline and during the first 8 weeks of treatment encompasses troponin, CRP, creatine kinase (CK), and brain natriuretic peptide (BNP)<sup>13,242,310,312,315</sup> are highly sensitive markers for CIM.

Importantly, while monitoring of clinical symptoms is important to inform CIM diagnosis, confirmation of a suspected CIM should rely primarily on objective parameters, that is, laboratory parameters exceeding pre-specified thresholds (Figure 3(b) and Table 3), to prevent premature and unnecessary discontinuation but also to ensure patient safety in cases of unspecific clinical symptoms.<sup>310</sup> Clearly established CIM necessitates immediate termination of clozapine,<sup>246,310</sup> strict avoidance of major physical activity,<sup>244</sup> and initiation of a cardioprotective pharmacotherapy with a

beta-blocker and an angiotensin-converting enzyme (ACE) inhibitor.<sup>73,241,242,246,316</sup> Serious cases of CIM might require treatment in an intensive care unit.<sup>4,244,317</sup> Severe outcomes of CIM – typically as a consequence of delayed or missed diagnosis and treatment<sup>318</sup> – include ventricular arrhythmia, persistent heart failure, and sudden death.<sup>158,244,246,312</sup> Importantly, early intervention increases the chance for a *restitutio ad integrum*,<sup>242</sup> underscoring the relevance of CIM screening during the initial titration of clozapine.<sup>318</sup>

Based on its early onset and titration speed dependency, a hypersensitivity reaction is discussed as a likely pathophysiological mechanism of CIM,<sup>235,244,246,319–323</sup> but current evidence remains inconclusive.<sup>157</sup> Thus far, no reliable predictors for an individual's CIM risk have been established. Several risk factors for CIM, however, have been identified,<sup>157</sup> chiefly among them concurrent treatment with valproate.<sup>157,237,324</sup> Consequently, valproate should not be prescribed concurrently with clozapine, neither for treatment of any residual psychopathology nor for seizures. There is also preclinical and clinical evidence that rapid titration increases the risk of CIM.<sup>237,319,325</sup> This suggests that people with slow clozapine metabolism might be at a higher risk for CIM. Higher age and higher clozapine doses also appear to constitute risk factors.<sup>157,326</sup>

Cardiomyopathy constitutes another potential cardiac side effect with reported incidence rates ranging between 0.02% and 1%.<sup>215,222</sup> Importantly, undetected and self-limiting myocarditis has been implicated as a likely cause.<sup>198,215,222</sup> Hence, prevention and adequate management of CIM might also reduce the risk of clozapine-associated cardiomyopathy.

#### *Gastrointestinal side effects*

The most common gastrointestinal side-effect is constipation, which occurs in up to 60% of patients.<sup>327–329</sup> Furthermore, at least 50% of patients show unambiguous evidence of CIGH in colonic transit studies.<sup>327</sup> Potentially severe consequences of CIGH include dysphagia, ileus, intestinal obstruction, bowel ischemia, and megacolon,<sup>328,329</sup> which are associated with a considerable mortality rate.<sup>330</sup> Importantly, the prevalence of CIGH is markedly higher than the prevalence of CIM and CIA.<sup>329,331</sup> CIGH arises primarily due to the anticholinergic and antiserotonergic effects of clozapine<sup>176</sup> and shows a clear dose dependence.<sup>167,327</sup> Polypharmacy,

which adds to clozapine's inherent anticholinergic load or otherwise affects gastrointestinal motility, constitutes a risk factor for CIGH.<sup>209,210</sup> As a first step, prevention and management of CIGH requires lifestyle and dietary modifications, that is, physical exercise, sufficient fluid intake, and fiber supplementation. As a second-line approach, current guidelines recommend specific pharmacological treatment including laxatives (first line: osmotic laxatives, second line: stimulant laxatives), prosecretory agents, and serotonergic agonists.<sup>207,208,211</sup>

#### *Metabolic side effects*

Irrespective of medication, patients with schizophrenia have an increased risk for developing a metabolic syndrome, encompassing hypertension, dyslipidemia, obesity, and diabetes.<sup>168–170</sup> For clozapine, the prevalence of metabolic syndrome is estimated to be approximately 50%.<sup>332,333</sup> Weight gain represents a crucial risk factor for developing metabolic syndrome<sup>334</sup> and an important psychological stressor.<sup>177,335–337</sup> Moreover, it reduces quality of life,<sup>335</sup> treatment adherence,<sup>337,338</sup> and contributes to cognitive dysfunction.<sup>339–341</sup> Importantly, weight gain typically occurs during the early stages of antipsychotic treatment.<sup>342,343</sup> More than two-thirds of patients show a gain of more than 7% of their baseline weight during the first year of treatment.<sup>177,344,345</sup> This underscores the necessity of frequent monitoring of body weight and metabolic parameters and of early weight-stabilizing interventions (Table 4).<sup>333,346</sup> Regular physical exercise, a Mediterranean diet, and smoking cessation to decrease cardiovascular risk are the primary recommendations to counteract weight gain.<sup>226,347</sup> Among pharmacological interventions, adjunctive metformin shows a good safety profile and the best efficacy for stabilizing weight gain.<sup>177,178,348,349</sup> Consequently, the first guideline for metformin use during antipsychotic treatment advocates a routine early initiation in addition to behavioral interventions to most effectively minimize weight gain and cardiometabolic risk.<sup>177</sup> On average, treatment with metformin leads to a weight loss of about 3.2 kg. As the feasibility of reversing weight gain remains limited, weight stabilization should be the primary goal. The recommended daily dose of metformin is 2000 mg when tolerable. Gastrointestinal issues such as nausea, diarrhea and vomiting as well as lactic acidosis are the most relevant side effects. Before and during treatment with metformin, renal function and vitamin B<sub>12</sub> level should be monitored routinely.

More recent findings indicate that glucagon-like peptide-1 (GLP1) receptor agonists could also be effective for mitigating clozapine-associated metabolic comorbidity.<sup>180</sup> Topiramate can also be considered as its efficacy appears to be comparable with metformin.<sup>181–184,352</sup> Recently, samidorphan – an opioid receptor antagonist – was introduced as an adjunctive treatment for olanzapine-associated weight gain.<sup>353,354</sup> This might be also a promising approach for clozapine.

Treatment of manifest diabetes in patients treated with clozapine should closely follow current guidelines including the use of insulin when indicated.<sup>355,356</sup> Adequate antidiabetic treatment substantially reduces cardiovascular risk and the risk for ketoacidosis or hyperosmolar coma.<sup>274</sup> Importantly, pre-existing diabetes mellitus in patients with TRS does not constitute a contraindication for clozapine treatment,<sup>357</sup> but rather requires intensified antidiabetic treatment. This is underscored by converging findings indicating that, for clozapine, the risk for diabetes is not excessive compared with second-generation antipsychotics as a whole, but rather falls in the higher range within this class of drugs.<sup>343,358</sup> In conclusion, it needs to be emphasized that strict management of metabolic side effects can notably improve the associated cardiovascular risk factors<sup>359</sup> and that overall clozapine treatment is actually associated with a relevant reduction of cardiovascular mortality.<sup>15,46</sup>

#### *Hypersalivation and pneumonia*

Clozapine-induced hypersalivation (CIH) constitutes a frequent side-effect with incidence rates ranging between 30% and 92%, which typically occurs early during treatment and shows no clear dose dependence.<sup>187,360</sup> Agonism at muscarinic M4 receptors and antagonism at  $\alpha$ 2-adrenergic receptors have primarily been implicated in its etiology.<sup>188,361,362</sup> Predominantly, patients report nightly hypersalivation.<sup>187</sup> CIH can cause psychological distress due to embarrassment and social stigma, as well as lead to somatic adverse events like skin irritation, parotitis, and aspiration pneumonia.<sup>73,194</sup> Management of CIH commonly requires early pharmacological intervention, usually with anticholinergic, that is, antimuscarinic, drugs. Evidence for their efficacy remains limited, however. Moreover, systemically acting drugs such as pirenzepine increase the overall anticholinergic load, raising the risk for CIGH.<sup>209,210,363</sup> Sublingual administration of atropine eye

drops<sup>73,364,365</sup> and regular botulinum toxin injections into the parotid and submandibular glands can avoid this problem.<sup>195,366</sup> Before recommending treatment with sublingual atropine eye drops, prescribers need to ensure that patients can adequately follow instructions regarding the finely dosed topical application to prevent accidental ingestion of relevant amounts of fluid. Importantly, CIH increases the risk of clozapine-associated pneumonia *via* salivary aspiration.<sup>367</sup> In this context, it is crucial to acknowledge the higher mortality rates of patients with schizophrenia due to pneumonia and increased rates for additional pulmonary diseases including chronic obstructive pulmonary disease.<sup>368</sup> Importantly, pneumonia elevates CRP levels, thus decreasing CYP1A2 enzyme activity and increasing plasma clozapine levels.<sup>105,369–372</sup> This underscores the necessity for preventive measures for clozapine-associated pneumonia. Furthermore, health care professionals should ensure a sufficient vaccination status of their patients for respiratory diseases including COVID-19 and influenza in order to reduce mortality rates.<sup>368,373</sup>

#### *Sedation*

Clozapine-induced sedation (CIS) ranks among the most commonly reported side-effects.<sup>189,374–376</sup> It shows a clear dose dependence, but is often at least partly transient.<sup>88,190,234,377</sup> Importantly, while there are established protocols regarding other important side-effects, data regarding the management of CIS remain limited, despite the relevance of CIS as a key determinant of treatment adherence.<sup>80,87,88,189,234</sup> Management of CIS should start with patient education about its potentially transient nature<sup>190</sup> and about healthy habits regarding sleep hygiene.<sup>190</sup> It also includes minimizing daytime clozapine administration, avoiding concomitant sedating drugs and clozapine dose reduction whenever possible.<sup>190,234,378</sup> Importantly, recent findings indicate that clozapine administration partly during daytime may not reduce the burden of sedation.<sup>379</sup> Emphasizing nocturnal administration whenever possible while taking into account individual preferences appears to be more promising also given that complex dosing instructions might be too demanding for some patients.<sup>379</sup> Adding aripiprazole constitutes another option.<sup>88,378</sup> Augmentation with modafinil has also been discussed, but findings from a placebo-controlled pilot trial were not generally supportive.<sup>73,380</sup> Furthermore, there are reports indicating a pharmacokinetic interaction between clozapine and

modafinil, which could lead to a considerable increase of clozapine plasma levels.<sup>381</sup>

### **Discontinuation and re-challenge of clozapine**

#### *Managing discontinuation*

Approximately 30–40% of patients discontinue clozapine over the course of treatment,<sup>382</sup> mainly because of side effects, non-compliance to monitoring protocols or patient preference.<sup>234,383</sup> Both immediate and gradual clozapine termination can result in withdrawal symptoms, especially cholinergic and serotonergic discontinuation syndrome.<sup>276,384–387</sup>

Cholinergic rebound symptoms observed in up to 50% of cases include agitation, delirium, and hallucinations,<sup>386</sup> vomiting, diarrhea, headache, diaphoresis, dystonia, and dyskinesia.<sup>384,385,388</sup> Clinical management includes supportive care and treatment with anticholinergic compounds.<sup>386</sup> Serotonergic rebound symptoms comprise agitation, diaphoresis, clonus, and hyperreflexia. In addition to supportive care, termination of concomitant serotonergic medication might be indicated as well as short-term use of cyproheptadine for moderate and severe cases.<sup>385</sup> Current evidence supports olanzapine as well as risperidone and long-acting aripiprazole as the best alternative options,<sup>389,390</sup> but without matching the efficacy of a clozapine re-challenge.<sup>391–393</sup>

Hence, discontinuation of clozapine often leads to a considerable worsening of psychopathology with potentially severe short- and long-term clinical and functional consequences.<sup>217,389,390,394–396</sup> While withdrawal symptoms also contribute to this deterioration, supersensitivity mechanisms<sup>397–401</sup> and a lack of sufficiently effective alternative antipsychotics are regarded as the main causes.<sup>384</sup> Catatonia and persistent psychotic exacerbation are the most common sequelae.<sup>386,397,402</sup> Here, benzodiazepines and electroconvulsive therapy (ECT) constitute crucial treatment options.<sup>402–404</sup> There is no evidence for a sufficient medium- and long-term efficacy of ECT without clozapine in most patients with TRS, however.<sup>395,405</sup>

Based on these findings, current guidelines strongly recommend a hyperbolic discontinuation regime, if discontinuation is inevitable.<sup>217,385,406</sup> Immediate termination of clozapine should be

limited to potentially life-threatening side effects including agranulocytosis, myocarditis, ileus or subileus, neuroleptic malignant syndrome (NMS), venous thromboembolism, and diabetic ketoacidosis or hyperosmolar coma.<sup>217</sup> Most importantly, because of the complications outlined above and its superior efficacy, permanent discontinuation of clozapine should be avoided whenever possible.<sup>217,221</sup>

Rather, the singular status of clozapine underscores the importance to seriously consider a re-challenge even after severe side-effects. This notion is supported by a growing body of evidence for a positive risk–benefit ratio and considerable success rates for clozapine re-challenges after neutropenia,<sup>217,395</sup> NMS,<sup>407</sup> and to a lesser extent myocarditis.<sup>224,408,409</sup> Any re-challenge must only be attempted in an appropriate hospital setting with sufficient support by relevant specialists, that is, cardiologists or hematologists.<sup>224,410</sup>

#### *Re-challenge after neutropenia*

Current evidence clearly argues against a re-challenge after CIA.<sup>269,407</sup> After CIN, a re-challenge based on a strict risk–benefit assessment is considered to be a reasonable clinical option.<sup>407</sup> Importantly, time of onset of CIN during a re-challenge is typically shorter.<sup>411</sup> In general, a slower re-titration rate of clozapine might reduce risk of re-occurrence of CIN.<sup>221</sup> Based on published cases, the success rate is estimated at about 66%.<sup>407</sup> Current evidence indicates that concomitant treatment with lithium markedly increases success rates.<sup>269,412,413</sup> Plasma lithium levels above 0.4 mmol/L have consistently been associated with increased neutrophil counts, most likely due to bone marrow induction.<sup>269,414–416</sup> Lithium treatment should be initiated at least two weeks prior to a clozapine re-challenge and maintained long-term,<sup>217</sup> because its discontinuation increases the risk for a re-occurrence of blood dyscrasia.<sup>412</sup> While it is overall considered to be safe, concomitant treatment with clozapine and lithium can markedly decrease the seizure threshold.<sup>151,417,418</sup>

Treatment with G-CSF is an alternative approach, which increases re-challenge success rates.<sup>287,291,419,420</sup> To this end, G-CSF can be administered on a regular prophylactic basis during a re-challenge irrespective of current absolute neutrophil count (ANC).<sup>421</sup> Alternatively, G-CSF can be administered on an as-required basis in the

event of predefined neutrophil counts to maintain clozapine treatment. Current evidence indicates that both approaches are safe and effective.<sup>421</sup> Importantly, currently available evidence indicates that long-term use of G-CSF is not associated with significant morbidity in other patient populations.<sup>422</sup> Therefore, such a strategy has been proposed for patients in which discontinuation of G-CSF results in recurrent neutropenia.<sup>421</sup> Long-term safety and efficacy data are currently lacking, however.<sup>419,421,423–426</sup>

To summarize, lithium can be suitable for persistent forms of mild neutropenia, while more severe forms of neutropenia require the use of G-CSF.

#### *Re-challenge after myocarditis*

At present, there are no established consensus guidelines for re-challenges after CIM, but rather protocols based on case series.<sup>243,309,315,407,410,427–431</sup> Importantly, a re-challenge should only be attempted after patients have made a full recovery from CIM.<sup>427</sup> It requires intensive clinical, laboratory and electrophysiological (ECG, TTE) monitoring (e.g. every second to third day) and very slow dose titration (e.g. 12.5–25 mg per week),<sup>243,408–410,427,432</sup> which reduces CIM recidivism risk.<sup>315,427</sup> Re-challenge success rates after CIM are currently estimated at approximately 60%,<sup>431</sup> but with a high degree of uncertainty. Notably, compared with re-challenges after CIN, the number of published cases is an order of a magnitude lower.<sup>407</sup> Therefore, re-challenges after CIM must not be regarded as a routine procedure and warrant exceptional caution.

#### **Pregnancy and breastfeeding**

A switch from a non-clozapine antipsychotic to clozapine might increase fertility as a result of alleviated hyperprolactinemia and amenorrhea.<sup>73</sup> Currently, there is no evidence for a reduced safety of clozapine for pregnant women.<sup>433</sup> Several side-effects, however, may be exacerbated including weight gain, constipation, sedation, and orthostatic hypotension.<sup>434</sup> Close monitoring for emerging gestational diabetes is therefore mandatory.<sup>435,436</sup> Notably, CYP1A2 enzyme activity decreases by approximately 33% during the first trimester and by approximately 65% during the last trimester.<sup>437</sup> This necessitates monthly monitoring of plasma clozapine levels throughout pregnancy, repeated a week after delivery.<sup>73</sup>

To date, there is no conclusive evidence for detrimental neurodevelopmental and cognitive long-term effects resulting from fetal exposure to clozapine.<sup>434,438–440</sup> Clozapine is not associated with greater teratogenic effects than other antipsychotics.<sup>440–442</sup> Furthermore, there is no evidence for increased rates of prematurity, delivery complications, or changes in birth weight and height compared with other antipsychotics.<sup>434</sup> Given its unique efficacy for TRS, for the majority of pregnant women receiving clozapine, switching to another antipsychotic is not a feasible option.<sup>434,436</sup> In most cases, the considerable risk for illness exacerbation associated with such a switch outweighs the risks associated with continued clozapine treatment during pregnancy.<sup>436,439</sup> Therefore, a thorough risk-benefit assessment is indispensable before any treatment change. Using the lowest effective dose of clozapine is especially crucial during pregnancy, however.<sup>73,433,434,436,438</sup> Furthermore, frequent gynecological consultations and antenatal screenings should be encouraged and supported.<sup>73,433,434,436,438</sup>

The level of clozapine excretion into breast milk is considerable.<sup>436,438</sup> Owing to insufficient short- and long-term safety data, breastfeeding during clozapine treatment should therefore be avoided.<sup>434</sup>

#### **Clozapine treatment in the elderly**

There are a number of changes in the pharmacokinetics and pharmacodynamics of clozapine in elderly patients, which warrant particular caution including lower maintenance doses.<sup>73,443,444</sup> Rates of CIA, CIMs, seizures, and metabolic syndrome increase in older patients.<sup>445–447</sup> The anticholinergic properties of clozapine may increase the risk for cognitive decline.<sup>91</sup> Overall, clozapine appears to be both safe and effective in the majority of elderly people when adhering to very low dose titrations and providing increased pharmacovigilance.<sup>443</sup>

#### **Management of clozapine-resistant schizophrenia**

The markedly delayed onset of its full therapeutic effect is a unique characteristic of clozapine, which appears to be only partly attributable to the necessarily slow initial dose titration.<sup>79,448</sup> Consequently, the current TRIP consensus guidelines strongly recommend deferring treatment evaluation in accordance with the main

**Table 4.** Management of clozapine-resistant schizophrenia.

Predominant persistent symptoms	Recommended augmentation strategies <sup>350,351</sup>
Positive symptoms and combined positive and negative symptoms	<ul style="list-style-type: none"><li>• Intensify CBT and psychosocial interventions</li><li>• ECT</li><li>• Add-on treatment with amisulpride or aripiprazole</li></ul>
Negative symptoms	<ul style="list-style-type: none"><li>• Intensify CBT and psychosocial interventions</li><li>• Add-on treatment with antidepressants (i.e. SSRI)</li><li>• Add-on treatment with mood stabilizer (avoid valproate)</li><li>• ECT</li></ul>
Suicidality	<ul style="list-style-type: none"><li>• Mood stabilizers (lithium or lamotrigine, avoid valproate)</li><li>• Antidepressant</li><li>• ECT</li></ul>
Aggressive behavior	<ul style="list-style-type: none"><li>• Add-on treatment with mood stabilizer or another antipsychotic drug</li></ul>
CBT, cognitive behavioral therapy; ECT, electroconvulsive therapy; SSRI, selective serotonin re-uptake inhibitor.	

target symptoms while also ensuring a plasma clozapine level above 350 µg/L (Table 4).<sup>350</sup> For predominant positive and mixed (both negative and positive symptoms) symptoms, treatment evaluation after three months is considered to be adequate.<sup>350</sup> For negative and cognitive symptoms, an evaluation after four months is recommended, while eight weeks are deemed appropriate for aggression and suicidality.<sup>350</sup>

About 40% of patients show an insufficient response to clozapine despite clozapine plasma levels within the recommended range.<sup>25,67,350</sup> These cases are classified as ultra-treatment-resistant or clozapine-resistant schizophrenia (CRS).<sup>25</sup> A high genetic load for schizophrenia appears to increase the risk for a poor treatment response.<sup>33,449</sup> Compared with TRS, CRS is characterized by later clozapine initiation and associated with higher mortality rates.<sup>127,350</sup> Importantly, clozapine should not be discontinued in patients with CRS, but rather augmented (Table 3).<sup>127,350</sup> For predominant positive symptoms, recommended augmentation strategies include a combination with

amisulpride or aripiprazole as well as ECT.<sup>350,351</sup> Furthermore, while there is no evidence for clinically meaningful symptom improvements produced by cognitive behavioral therapy (CBT) in CRS, pragmatic individual trials might still be indicated.<sup>450</sup>

### Impact on mortality

Despite its side-effect burden and its detrimental influence on metabolic parameters in particular, clozapine reduces not only suicide mortality but also all-cause mortality to a greater degree than any other oral antipsychotic. Its positive effects on cardiovascular mortality – while less pronounced – are nonetheless comparable with other antipsychotics.<sup>15,46,451</sup> Clozapine's mortality reducing effects are likely attributable to its superior efficacy regarding positive symptoms and suicidality, to improved treatment adherence and relapse rates,<sup>46</sup> as well as to mitigating the increased mortality risk associated with comorbid SUDs.<sup>452</sup> Consequently, the likelihood of an adequate diagnosis and treatment of somatic comorbidities should also increase.<sup>453</sup> This might also be facilitated partly by the stricter pharmacovigilance regime required for clozapine. In light of the high rates of somatic comorbidities and the considerable overall increased mortality rates in people with schizophrenia,<sup>454,455</sup> these findings constitute another crucial argument in favor of a broader use of clozapine while also underscoring its safety.<sup>456</sup>

### Clinical implications

The singular extent of clozapine's efficacy outlined above has important clinical implications for the treatment of schizophrenia. First and foremost, existing clinical and neurobiological lines of evidence provide little to no reason to be reluctant regarding clozapine use. Consequently, clozapine must never be regarded as an antipsychotic of 'last resort' but rather the drug of choice for patients nonresponsive to first-line treatment and more generally for patients with an emerging unfavorable course of illness.<sup>457</sup> In this regard, stringent use of TRS criteria and close adherence to current recommendations provide excellent guidance for clinical decision-making. The high rates of treatment resistance in first-episode patients underscore the need for early recognition and treatment of TRS.

Slow dose titration is essential to avoid titration-related side effects including sedation, myocarditis,

and neutropenia. To this end, dose titration rates of 12.5 mg per day or less during the initial weeks of treatment should be seriously considered. Systematic pharmacovigilance and a timely management of ADRs are very feasible and also among the most important elements of a successful treatment strategy. Furthermore, clozapine might be essential when aiming to address substance abuse and sufficient treatment of somatic comorbidities. Even major pre-existing problems in these areas should not automatically be regarded as obstacles for offering clozapine.<sup>458</sup> After clozapine initiation, clinicians should exhaust every reasonable option to minimize permanent all-cause discontinuation. This includes carefully re-challenging patients even after serious adverse events like myocarditis and neutropenia. Furthermore, treatment algorithms involving clozapine can and should be very simple. Clozapine use is key for reducing antipsychotic polypharmacy and the associated side-effect burden.<sup>459</sup> Accordingly, clozapine should always first be used as an antipsychotic monotherapy in both TRS and non-TRS patients. For persistent positive symptoms despite adequate clozapine use, augmentation with an appropriate second antipsychotic should be the first treatment escalation (Table 4), before offering ECT as a second treatment escalation step. Finally, clozapine use requires a long-term approach acknowledging the late onset of clozapine's full effects. In this context, clinicians also need to be mindful of the fact that some key benefits like reduced suicidality and mortality rates may be next to invisible.

## Conclusion

Underutilization and delayed initiation of clozapine regardless of the continuously mounting evidence and contrary to all recommendations remain a major concern. This underscores the urgent need for intensified research into the real and perceived barriers for clozapine treatment, continued education of psychiatrists, and appropriate structural adjustments of routine clinical care. These efforts are justified not least by the very high patient satisfaction with clozapine despite the considerable complexity of its use and its potential side effects.<sup>10,286,460</sup> Most importantly however, they are imperative because – going into the sixth decade of its clinical use – compared with all other available pharmacological treatment options, the broad beneficial impact of clozapine on patients' life remains second to none.

## Declarations

### *Ethics approval and consent to participate*

Not applicable.

### *Consent for publication*

Not applicable.

### *Author contributions*

**Mishal Qubad:** Conceptualization; Methodology; Visualization; Writing – original draft; Writing – review & editing.

**Robert A. Bittner:** Conceptualization; Methodology; Supervision; Writing – original draft; Writing – review & editing.

### *Acknowledgements*

The authors thank Martina Hahn, Alkomiet Hasan, and G. Herzog for comments on an earlier version of this manuscript.

### *Funding*

The authors received no financial support for the research, authorship, and/or publication of this article.

### *Competing interests*

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### *Availability of data and materials*

Not applicable.

## ORCID iDs

Mishal Qubad  <https://orcid.org/0000-0002-9291-5739>

Robert A. Bittner  <https://orcid.org/0000-0003-2021-0358>

## References

1. Simeone JC, Ward AJ, Rotella P, *et al.* An evaluation of variation in published estimates of schizophrenia prevalence from 1990–2013: a systematic literature review. *BMC Psychiatry* 2015; 15: 193.
2. McGrath J, Saha S, Chant D, *et al.* Schizophrenia: a concise overview of incidence, prevalence, and mortality. *Epidemiol Rev* 2008; 30: 67–76.

3. World Health Organization. *The world health report: 2001: mental health: new understanding, new hope*. Geneva: World Health Organization, 2001.
4. Carbon M and Correll CU. Clinical predictors of therapeutic response to antipsychotics in schizophrenia. *Dialogues Clin Neurosci* 2014; 16: 505–524.
5. Kane JM, Agid O, Baldwin ML, *et al*. Clinical guidance on the identification and management of treatment-resistant schizophrenia. *J Clin Psychiatry* 2019; 80: 18com12123.
6. Meltzer HY. Treatment-resistant schizophrenia – the role of clozapine. *Curr Med Res Opin* 1997; 14: 1–20.
7. Potkin SG, Kane JM, Correll CU, *et al*. The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. *NPJ Schizophr* 2020; 6: 1.
8. Kane J, Honigfeld G, Singer J, *et al*. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. *Arch Gen Psychiatry* 1988; 45: 789–796.
9. Leucht S, Corves C, Arbter D, *et al*. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. *Lancet* 2009; 373: 31–41.
10. Lewis SW, Barnes TR, Davies L, *et al*. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. *Schizophr Bull* 2006; 32: 715–723.
11. McEvoy JP, Lieberman JA, Stroup TS, *et al*. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; 163: 600–610.
12. Siskind D, McCartney L, Goldschlager R, *et al*. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2016; 209: 385–392.
13. Correll CU, Agid O, Crespo-Facorro B, *et al*. A guideline and checklist for initiating and managing clozapine treatment in patients with treatment-resistant schizophrenia. *CNS Drugs* 2022; 36: 659–679.
14. Huhn M, Nikolakopoulou A, Schneider-Thoma J, *et al*. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. *Lancet* 2019; 394: 939–951.
15. Taipale H, Tanskanen A, Mehtälä J, *et al*. 20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20). *World Psychiatry* 2020; 19: 61–68.
16. Leitliniengruppe DeVHfrd. S3-Leitlinie Schizophrenie. Langfassung. Version 1.0, 2019, <https://register.awmf.org/de/leitlinien/detail/038-009>
17. Addington D, Abidi S, Garcia-Ortega I, *et al*. Canadian guidelines for the assessment and diagnosis of patients with schizophrenia spectrum and other psychotic disorders. *Can J Psychiatry* 2017; 62: 594–603.
18. Buckley PF. Treatment-resistant schizophrenia. *Focus* 2020; 18: 364–367.
19. Hasan A, Falkai P, Wobrock T, *et al*. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia part 3: update 2015 management of special circumstances: depression, suicidality, substance use disorders and pregnancy and lactation. *World J Biol Psychiatry* 2015; 16: 142–170.
20. Remington G, Addington D, Honer W, *et al*. Guidelines for the pharmacotherapy of schizophrenia in adults. *Can J Psychiatry* 2017; 62: 604–616.
21. Bachmann CJ, Aagaard L, Bernardo M, *et al*. International trends in clozapine use: a study in 17 countries. *Acta Psychiatr Scand* 2017; 136: 37–51.
22. Taylor D. Reply. *Acta Psychiatrica Scand* 2014; 130: 157–157.
23. Verdoux H, Quiles C, Bachmann CJ, *et al*. Prescriber and institutional barriers and facilitators of clozapine use: a systematic review. *Schizophr Res* 2018; 201: 10–19.
24. Nielsen J, Dahm M, Lublin H, *et al*. Psychiatrists' attitude towards and knowledge of clozapine treatment. *J Psychopharmacol* 2010; 24: 965–971.
25. Howes OD, McCutcheon R, Agid O, *et al*. Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. *Am J Psychiatry* 2017; 174: 216–229.
26. Howes OD, Thase ME and Pillinger T. Treatment resistance in psychiatry: state of the art and new directions. *Mol Psychiatry* 2021; 27: 58–72.
27. McCutcheon R, Beck K, D'Ambrosio E, *et al*. Antipsychotic plasma levels in the assessment of

- poor treatment response in schizophrenia. *Acta Psychiatr Scand* 2018; 137: 39–46.
28. Hiemke C, Bergemann N, Clement HW, *et al.* Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. *Pharmacopsychiatry* 2018; 51: 9–62.
  29. Schoretsanitis G, Kane JM, Correll CU, *et al.* Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of Clinical Psychopharmacology and the Therapeutic Drug Monitoring Task Force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie. *J Clin Psychiatry* 2020; 81: 19cs13169.
  30. Demjaha A, Lappin JM, Stahl D, *et al.* Antipsychotic treatment resistance in first-episode psychosis: prevalence, subtypes and predictors. *Psychol Med* 2017; 47: 1981–1989.
  31. Lally J, Ajnakina O, Di Forti M, *et al.* Two distinct patterns of treatment resistance: clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. *Psychol Med* 2016; 46: 3231–3240.
  32. Chan SKW, Chan HYV, Honer WG, *et al.* Predictors of treatment-resistant and clozapine-resistant schizophrenia: a 12-year follow-up study of first-episode schizophrenia-spectrum disorders. *Schizophr Bull* 2021; 47: 485–494.
  33. Frank J, Lang M, Witt SH, *et al.* Identification of increased genetic risk scores for schizophrenia in treatment-resistant patients. *Mol Psychiatry* 2015; 20: 150–151.
  34. Wimberley T, Støvring H, Sørensen HJ, *et al.* Predictors of treatment resistance in patients with schizophrenia: a population-based cohort study. *Lancet Psychiatry* 2016; 3: 358–366.
  35. Costas-Carrera A, Garcia-Rizo C, Bitanirhw B, *et al.* Obstetric complications and brain imaging in schizophrenia: a systematic review. *Biol Psychiatry Cogn Neurosci Neuroimaging* 2020; 5: 1077–1084.
  36. Elkis H and Buckley PF. Treatment-resistant schizophrenia. *Psychiatr Clin North Am* 2016; 39: 239–265.
  37. Li KJ, Solomon HV and DeLisi LE. Clozapine pharmacogenomics: a review of efficacy, pharmacokinetics, and agranulocytosis. *Curr Opin Psychiatry* 2018; 31: 403–408.
  38. Mouchlianitis E, McCutcheon R and Howes OD. Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. *Lancet Psychiatry* 2016; 3: 451–463.
  39. Correll CU and Howes OD. Treatment-resistant schizophrenia: definition, predictors, and therapy options. *J Clin Psychiatry* 2021; 82: MY20096AH1C.
  40. Kinon BJ. The group of treatment resistant schizophrenias. Heterogeneity in treatment resistant schizophrenia (TRS). *Front Psychiatry* 2018; 9: 757.
  41. Wada M, Noda Y, Iwata Y, *et al.* Dopaminergic dysfunction and excitatory/inhibitory imbalance in treatment-resistant schizophrenia and novel neuromodulatory treatment. *Mol Psychiatry* 2022; 27: 2950–2967.
  42. Fusar-Poli L, Rutten BPF, van Os J, *et al.* Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype? *Int Rev Psychiatry*. Epub ahead of print 27 July 2022. DOI: 10.1080/09540261.2022.2101352.
  43. Gasse C, Wimberley T, Wang Y, *et al.* Schizophrenia polygenic risk scores, urbanicity and treatment-resistant schizophrenia. *Schizophr Res* 2019; 212: 79–85.
  44. Chakos M, Lieberman J, Hoffman E, *et al.* Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. *Am J Psychiatry* 2001; 158: 518–526.
  45. Mizuno Y, McCutcheon RA, Brugger SP, *et al.* Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis. *Neuropsychopharmacology* 2020; 45: 622–631.
  46. Wagner E, Sifakis S, Fernando P, *et al.* Efficacy and safety of clozapine in psychotic disorders—a systematic quantitative meta-review. *Transl Psychiatry* 2021; 11: 487.
  47. Reid WH and Mason M. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system. *J Clin Psychiatry* 1998; 59: 189–194.
  48. Stroup TS, Gerhard T, Crystal S, *et al.* Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia. *Am J Psychiatry* 2016; 173: 166–173.
  49. Tiihonen J, Haukka J, Taylor M, *et al.* A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Am J Psychiatry* 2011; 168: 603–609.
  50. Tiihonen J, Mittendorfer-Rutz E, Majak M, *et al.* Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. *JAMA Psychiatry* 2017; 74: 686–693.

51. Tiihonen J, Wahlbeck K, Lönnqvist J, *et al.* Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. *BMJ* 2006; 333: 224.
52. Lähteenvuo M, Luykx JJ, Taipale H, *et al.* Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts. *Br J Psychiatry* 2022; 221: 758–765.
53. St pnicki P, Kondej M and Kaczor AA. Current concepts and treatments of schizophrenia. *Molecules* 2018; 23: 2087.
54. Siris SG. Suicide and schizophrenia. *J Psychopharmacol* 2001; 15: 127–135.
55. Meltzer HY, Alphs L, Green AI, *et al.* Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). *Arch Gen Psychiatry* 2003; 60: 82–91.
56. Hennen J and Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. *Schizophr Res* 2005; 73: 139–145.
57. Meltzer HY. Clozapine: balancing safety with superior antipsychotic efficacy. *Clin Schizophr Relat Psychoses* 2012; 6: 134–144.
58. Frogley C, Taylor D, Dickens G, *et al.* A systematic review of the evidence of clozapine's anti-aggressive effects. *Int J Neuropsychopharmacol* 2012; 15: 1351–1371.
59. Patchan K, Vyas G, Hackman AL, *et al.* Clozapine in reducing aggression and violence in forensic populations. *Psychiatr Q* 2018; 89: 157–168.
60. Buchanan RW, Kreyenbuhl J, Kelly DL, *et al.* The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. *Schizophr Bull* 2010; 36: 71–93.
61. Citrome L, Volavka J, Czobor P, *et al.* Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. *Psychiatr Serv* 2001; 52: 1510–1514.
62. Krakowski MI, Czobor P, Citrome L, *et al.* Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. *Arch Gen Psychiatry* 2006; 63: 622–629.
63. Brunette MF, Drake RE, Xie H, *et al.* Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. *Schizophr Bull* 2006; 32: 637–643.
64. Agid O, Arenovich T, Sajeev G, *et al.* An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. *J Clin Psychiatry* 2011; 72: 1439–1444.
65. Kahn RS, Winter Van Rossum I, Leucht S, *et al.* Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. *Lancet Psychiatry* 2018; 5: 797–807.
66. Yoshimura B, Yada Y, So R, *et al.* The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study. *Psychiatry Res* 2017; 250: 65–70.
67. Siskind D, Siskind V and Kisely S. Clozapine response rates among people with treatment-resistant schizophrenia: data from a systematic review and meta-analysis. *Can J Psychiatry* 2017; 62: 772–777.
68. Jones R, Upthegrove R, Price MJ, *et al.* Duration of prior psychotic illness and clozapine response: a retrospective observational study using electronic health records. *Ther Adv Psychopharmacol*. Epub ahead of print 20 June 2022. DOI: 10.1177/20451253221103353.
69. Shah P, Iwata Y, Brown EE, *et al.* Clozapine response trajectories and predictors of non-response in treatment-resistant schizophrenia: a chart review study. *Eur Arch Psychiatry Clin Neurosci* 2020; 270: 11–22.
70. Griffiths K, Millgate E, Egerton A, *et al.* Demographic and clinical variables associated with response to clozapine in schizophrenia: a systematic review and meta-analysis. *Psychol Med* 2021; 51: 376–386.
71. John AP, Ko EKF and Dominic A. Delayed initiation of clozapine continues to be a substantial clinical concern. *Can J Psychiatry* 2018; 63: 526–531.
72. Meltzer HY, Bastani B, Ramirez L, *et al.* Clozapine: new research on efficacy and mechanism of action. *Eur Arch Psychiatry Neurol Sci* 1989; 238: 332–339.
73. Bleakley S and Taylor D. *Clozapine handbook*. Warwickshire: Lloyd-Reinhold Communications, 2013.
74. Hribkova H, Svoboda O, Bartecku E, *et al.* Clozapine reverses dysfunction of glutamatergic neurons derived from clozapine-responsive

- schizophrenia patients. *Front Cell Neurosci* 2022; 16: 830757.
75. McQueen G, Sendt K-V, Gillespie A, *et al.* Changes in brain glutamate on switching to clozapine in treatment-resistant schizophrenia. *Schizophr Bull* 2021; 47: 662–671.
  76. Moghaddam B and Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. *Neuropsychopharmacology* 2012; 37: 4–15.
  77. Tuominen HJ, Tiihonen J and Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. *Schizophr Res* 2005; 72: 225–234.
  78. Daskalakis ZJ and George TP. Clozapine, GABAB, and the treatment of resistant schizophrenia. *Clin Pharmacol Ther* 2009; 86: 442–446.
  79. Gammon D, Cheng C, Volkovinskaia A, *et al.* Clozapine: why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders? *Biomolecules* 2021; 11: 1030.
  80. Nair PC, McKinnon RA, Miners JO, *et al.* Binding of clozapine to the GABAB receptor: clinical and structural insights. *Mol Psychiatry* 2020; 25: 1910–1919.
  81. Fukuyama K, Kato R, Murata M, *et al.* Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor. *Biomolecules* 2019; 9: 234.
  82. Lidsky TI, Yablonsky-Alter E, Zuck L, *et al.* Anti-glutamatergic effects of clozapine. *Neurosci Lett* 1993; 163: 155–158.
  83. Veerman SR, Schulte PF and De Haan L. The glutamate hypothesis: a pathogenic pathway from which pharmacological interventions have emerged. *Pharmacopsychiatry* 2014; 47: 121–130.
  84. Seeman P. Clozapine, a fast-off-D2 antipsychotic. *ACS Chem Neurosci* 2014; 5: 24–29.
  85. Abela AR, Ji XD, Li Z, *et al.* Clozapine reliably increases the motivation for food: parsing the role of the 5-HT<sub>2c</sub> and H1 receptors. *Psychopharmacology* 2020; 237: 957–966.
  86. Gunes A, Melkersson KI, Scordo MG, *et al.* Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. *J Clin Psychopharmacol* 2009; 29: 65–68.
  87. De Berardis D, Rapini G, Olivieri L, *et al.* Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. *Ther Adv Drug Saf* 2018; 9: 237–256.
  88. Ramos Perdigüés S, Sauras Quecuti R, Mané A, *et al.* An observational study of clozapine induced sedation and its pharmacological management. *Eur Neuropsychopharmacol* 2016; 26: 156–161.
  89. Kim DD, Barr AM, Lu C, *et al.* Clozapine-associated obsessive-compulsive symptoms and their management: a systematic review and analysis of 107 reported cases. *Psychother Psychosom* 2020; 89: 151–160.
  90. Kim DD, Barr AM, White RF, *et al.* Clozapine-induced obsessive-compulsive symptoms: mechanisms and treatment. *J Psychiatry Neurosci* 2019; 44: 71–72.
  91. Kirrane A, Majumdar B and Richman A. Clozapine use in old age psychiatry. *BjPsych Adv* 2018; 24: 204–211.
  92. Skokou M, Karavia EA, Drakou Z, *et al.* Adverse drug reactions in relation to clozapine plasma levels: a systematic review. *Pharmaceuticals* 2022; 15: 817.
  93. Tanzer T, Warren N, McMahon L, *et al.* Treatment strategies for clozapine-induced nocturnal enuresis and urinary incontinence: a systematic review. *CNS Spectr*. Epub ahead of print 28 January 2022. DOI: 10.1017/S1092852922000050.
  94. Benkert O and Hippus H. *Kompendium der Psychiatrischen Pharmakotherapie*. Berlin: Springer, 2021.
  95. Jann MW, Grimsley SR, Gray EC, *et al.* Pharmacokinetics and pharmacodynamics of clozapine. *Clin Pharmacokinet* 1993; 24: 161–176.
  96. Haring C, Fleischhacker WW, Schett P, *et al.* Influence of patient-related variables on clozapine plasma levels. *Am J Psychiatry* 1990; 147: 1471–1475.
  97. Anderson SG, Livingston M, Couchman L, *et al.* Sex differences in plasma clozapine and norclozapine concentrations in clinical practice and in relation to body mass index and plasma glucose concentrations: a retrospective survey. *Ann Gen Psychiatry* 2015; 14: 39.
  98. Schoretsanitis G, Kane JM, Ruan CJ, *et al.* A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. *Expert Rev Clin Pharmacol* 2019; 12: 603–621.
  99. Haring C, Meise U, Humpel C, *et al.* Dose-related plasma levels of clozapine: influence of smoking behaviour, sex and age. *Psychopharmacology* 1989; 99(Suppl.): S38–S40.

100. Ng CH, Chong SA, Lambert T, *et al.* An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. *Int Clin Psychopharmacol* 2005; 20: 163–168.
101. Nielsen J, Damkier P, Lublin H, *et al.* Optimizing clozapine treatment. *Acta Psychiatr Scand* 2011; 123: 411–422.
102. Perry PJ, Bever KA, Arndt S, *et al.* Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. *Biol Psychiatry* 1998; 44: 733–738.
103. Olesen OV and Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. *J Clin Pharmacol* 2001; 41: 823–832.
104. Thorn CF, Müller DJ, Altman RB, *et al.* PharmGKB summary: clozapine pathway, pharmacogenetics. *Pharmacogenet Genomics* 2018; 28: 214–222.
105. Clark SR, Warren NS, Kim G, *et al.* Elevated clozapine levels associated with infection: a systematic review. *Schizophr Res* 2018; 192: 50–56.
106. De Leon J and Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2003; 27: 1059–1063.
107. Leung JG, Nelson S, Takala CR, *et al.* Infection and inflammation leading to clozapine toxicity and intensive care: a case series. *Ann Pharmacother* 2014; 48: 801–805.
108. Cranshaw T and Harikumar T. COVID-19 infection may cause clozapine intoxication: case report and discussion. *Schizophr Bull* 2020; 46: 751.
109. Tio N, Schulte PFJ and Martens HJM. Clozapine intoxication in COVID-19. *Am J Psychiatry* 2021; 178: 123–127.
110. Schoretsanitis G, Kane JM and De Leon J. Adding oral contraceptives to clozapine may require halving the clozapine dose: a new case and a literature review. *J Clin Psychopharmacol* 2020; 40: 308–310.
111. Lam YWF. Oral contraceptives and clozapine. *Brown Univ Psychopharm Update* 2020; 31: 2–3.
112. Faber MS, Jetter A and Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when. *Basic Clin Pharmacol Toxicol* 2005; 97: 125–134.
113. Barrangou-Pouey-Darlas M, Guerlais M, Laforgue EJ, *et al.* CYP1A2 and tobacco interaction: a major pharmacokinetic challenge during smoking cessation. *Drug Metab Rev* 2021; 53: 30–44.
114. Bondolfi G, Morel F, Crettol S, *et al.* Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. *Ther Drug Monit* 2005; 27: 539–543.
115. Bozikas VP, Papakosta M, Niopas I, *et al.* Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. *Eur Neuropsychopharmacol* 2004; 14: 39–44.
116. Chiu CC, Lu ML, Huang MC, *et al.* Heavy smoking, reduced olanzapine levels, and treatment effects: a case report. *Ther Drug Monit* 2004; 26: 579–581.
117. Chochol MD, Kataria L, O'Rourke MC, *et al.* Clozapine-associated myoclonus and stuttering secondary to smoking cessation and drug interaction: a case report. *J Clin Psychopharmacol* 2019; 39: 275–277.
118. Derenne JL and Baldessarini RJ. Clozapine toxicity associated with smoking cessation: case report. *Am J Ther* 2005; 12: 469–471.
119. Eap CB, Bender S, Jaquenoud Sirot E, *et al.* Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. *J Clin Psychopharmacol* 2004; 24: 214–219.
120. Faber MS and Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. *Clin Pharmacol Ther* 2004; 76: 178–184.
121. Van Der Weide J, Steijns LS and van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. *Pharmacogenetics* 2003; 13: 169–172.
122. Hukkanen J, Jacob P III, Peng M, *et al.* Effect of nicotine on cytochrome P450 1A2 activity. *Br J Clin Pharmacol* 2011; 72: 836–838.
123. Van Der Plas A, Pouly S, Blanc N, *et al.* Impact of switching to a heat-not-burn tobacco product on CYP1A2 activity. *Toxicol Rep* 2020; 7: 1480–1486.
124. Blacker CJ. Clinical issues to consider for clozapine patients who vape: a case illustration. *Focus* 2020; 18: 55–57.
125. Tomko JR, Ahmed N, Kuntz C, *et al.* A reasonable alternative to clozapine in the chronically relapsing smoking patient? a retrospective analysis. *Hosp Pharm* 2016; 51: 834–840.

126. Rubio JM and Kane JM. How and when to use clozapine. *Acta Psychiatr Scand* 2020; 141: 178–189.
127. Wagner E, Löhrs L, Siskind D, *et al.* Clozapine augmentation strategies – a systematic meta-review of available evidence. Treatment options for clozapine resistance. *J Psychopharmacol* 2019; 33: 423–435.
128. Stark A and Scott J. A review of the use of clozapine levels to guide treatment and determine cause of death. *Aust N Z J Psychiatry* 2012; 46: 816–825.
129. Kitchen D, Till A and Xavier P. Routine clozapine assay monitoring to improve the management of treatment-resistant schizophrenia. *BJPsych Bull* 2022; 46: 267–270.
130. Aldenhoff A-LSM and Messer T. Toxische Clozapin-Plasmaspiegel nach Zigarettenabstinenz. *Nervenheilkunde* 2008; 27: 78–79.
131. Hägg S, Spigset O, Edwardsson H, *et al.* Prolonged sedation and slowly decreasing clozapine serum concentrations after an overdose. *J Clin Psychopharmacol* 1999; 19: 282–284.
132. Sparve E, Nordberg P, Forsberg S, *et al.* Acute clozapine intoxication. *J Clin Psychopharmacol* 2009; 29: 302–304.
133. Jann MW. Do Asians patients require only half of the clozapine dose prescribed for Caucasians? A critical review. *Indian J Psychol Med* 2020; 42: 1–3.
134. Sachse C, Brockmöller J, Bauer S, *et al.* Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. *Br J Clin Pharmacol* 1999; 47: 445–449.
135. Zhou SF, Yang LP, Zhou ZW, *et al.* Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. *AAPS J* 2009; 11: 481–494.
136. Légaré N, Grégoire CA, De Benedictis L, *et al.* Increasing the clozapine: norclozapine ratio with co-administration of fluvoxamine to enhance efficacy and minimize side effects of clozapine therapy. *Med Hypotheses* 2013; 80: 689–691.
137. Lu ML, Lane HY, Chen KP, *et al.* Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. *J Clin Psychiatry* 2000; 61: 594–599.
138. Silver H. Fluvoxamine as an adjunctive agent in schizophrenia. *CNS Drug Rev* 2001; 7: 283–304.
139. Hinze-Selch D, Deuschle M, Weber B, *et al.* Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. *Psychopharmacology* 2000; 149: 163–169.
140. Polcwiartek C and Nielsen J. The clinical potentials of adjunctive fluvoxamine to clozapine treatment: a systematic review. *Psychopharmacology* 2016; 233: 741–750.
141. Wenzel-Seifert K, Wittmann M and Haen E. QTc prolongation by psychotropic drugs and the risk of Torsade de Pointes. *Dtsch Arztebl Int* 2011; 108: 687–693.
142. Wetzel H, Anghelescu I, Szegedi A, *et al.* Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study. *J Clin Psychopharmacol* 1998; 18: 2–9.
143. Sandson NB, Cozza KL, Armstrong SC, *et al.* Clozapine case series. *Psychosomatics* 2007; 48: 170–175.
144. Spina E, Pisani F and De Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. *Pharmacol Res* 2016; 106: 72–86.
145. Tóth K, Csukly G, Sirok D, *et al.* Potential role of patients' CYP3A-status in clozapine pharmacokinetics. *Int J Neuropsychopharmacol* 2017; 20: 529–537.
146. Tanzer TD, Brouard T, Pra SD, *et al.* Treatment strategies for clozapine-induced hypotension: a systematic review. *Ther Adv Psychopharmacol* 2022; 12.
147. De Berardis D, Serroni N, Campanella D, *et al.* Update on the adverse effects of clozapine: focus on myocarditis. *Curr Drug Saf* 2012; 7: 55–62.
148. Lucca J, Madhan R, Ram D, *et al.* Incidence and predictors of adverse drug reactions caused by drug-drug interactions in psychiatric patients – an empirical study. *Trop J Med Research* 2015; 19: 29–35.
149. Demler TL and Trigoboff E. Are clozapine blood dyscrasias associated with concomitant medications. *Innov Clin Neurosci* 2011; 8: 35–41.
150. Ibáñez L, Vidal X, Ballarín E, *et al.* Agranulocytosis associated with dipyrone (metamizol). *Eur J Clin Pharmacol* 2005; 60: 821–829.
151. Wong J and Delva N. Clozapine-induced seizures: recognition and treatment. *Can J Psychiatry* 2007; 52: 457–463.

152. Garcia G, Crismon ML and Dorson PG. Seizures in two patients after the addition of lithium to a clozapine regimen. *J Clin Psychopharmacol* 1994; 14: 426–428.
153. Yang SY, Liao YT, Liu HC, *et al.* Antipsychotic drugs, mood stabilizers, and risk of pneumonia in bipolar disorder: a nationwide case-control study. *J Clin Psychiatry* 2013; 74: e79–e86.
154. Dhillon R, Bastiampillai T, Tee K, *et al.* Clozapine and associated QTc prolongation. *Aust N Z J Psychiatry* 2011; 45: 1098–1099.
155. Grande I, Pons A, Baeza I, *et al.* QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment. *Hum Psychopharmacol* 2011; 26: 397–403.
156. Kang UG, Kwon JS, Ahn YM, *et al.* Electrocardiographic abnormalities in patients treated with clozapine. *J Clin Psychiatry* 2000; 61: 441–446.
157. Vickers M, Ramineni V, Malacova E, *et al.* Risk factors for clozapine-induced myocarditis and cardiomyopathy: a systematic review and meta-analysis. *Acta Psychiatr Scand* 2022; 145: 442–455.
158. Ronaldson KJ, Fitzgerald PB and McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. *Acta Psychiatr Scand* 2015; 132: 231–240.
159. Sangüesa E, Cirujeda C, Concha J, *et al.* Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: does UGT polymorphism affect these drug interactions? *Chem-Biol Interact* 2022; 364: 110042.
160. Costa-Dookhan KA, Agarwal SM, Chintoh A, *et al.* The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. *Expert Opin Drug Saf* 2020; 19: 43–57.
161. Kuoppamäki M, Syvälahti E and Hietala J. Clozapine and N-desmethylclozapine are potent 5-HT<sub>1C</sub> receptor antagonists. *Eur J Pharmacol* 1993; 245: 179–182.
162. Ellison JC and Dufresne RL. A review of the clinical utility of serum clozapine and norclozapine levels. *Ment Health Clin* 2015; 5: 68–73.
163. Tan MSA, Honarparvar F, Falconer JR, *et al.* A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. *Psychopharmacology* 2021; 238: 615–637.
164. Rajji TK, Mulsant BH, Davies S, *et al.* Prediction of working memory performance in schizophrenia by plasma ratio of clozapine to N-desmethylclozapine. *Am J Psychiatry* 2015; 172: 579–585.
165. Costa-Dookhan KA, Agarwal SM, Chintoh A, *et al.* The clozapine to norclozapine ratio: a narrative review of the clinical utility to minimize metabolic risk and enhance clozapine efficacy. *Expert Opin Drug Saf* 2020; 19: 43–57.
166. Couchman L, Morgan PE, Spencer EP, *et al.* Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993–2007. *Ther Drug Monit* 2010; 3232: 438–447.
167. De Berardis D, Rapini G, Olivieri L, *et al.* Safety of antipsychotics for the treatment of schizophrenia: a focus on the adverse effects of clozapine. *Ther Adv Drug Saf* 2018; 9: 237–256.
168. Correll CU, Robinson DG, Schooler NR, *et al.* Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. *JAMA Psychiatry* 2014; 71: 1350–1363.
169. De Hert M, Dekker JM, Wood D, *et al.* Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). *Eur Psychiatry* 2009; 24: 412–424.
170. Ventriglio A, Gentile A, Stella E, *et al.* Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management. *Front Neurosci* 2015; 9: 297.
171. Galletly C, Castle D, Dark F, *et al.* Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. *Aust N Z J Psychiatry* 2016; 50: 410–472.
172. Cohn TA and Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. *Can J Psychiatry* 2006; 51: 492–501.
173. Murtagh A, Petrovici R, Wong W, *et al.* Improving monitoring for metabolic syndrome using audit. *Ir J Psychol Med* 2011; 28: i–iv.
174. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, *et al.* Consensus development conference on antipsychotic drugs

- and obesity and diabetes. *Diabetes Care* 2004; 27: 596–601.
175. Citrome L and Volavka J. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. *Diabetes Care* 2004; 27: 2087–2088.
  176. Gurrera RJ, Gearin PF, Love J, *et al.* Recognition and management of clozapine adverse effects: a systematic review and qualitative synthesis. *Acta Psychiatr Scand* 2022; 145: 423–441.
  177. Fitzgerald I, O'Connell J, Keating D, *et al.* Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology. *Evid Based Ment Health* 2022; 25: 15–22.
  178. Zimbron J, Khandaker GM, Toschi C, *et al.* A systematic review and meta-analysis of randomised controlled trials of treatments for clozapine-induced obesity and metabolic syndrome. *Eur Neuropsychopharmacol* 2016; 26: 1353–1365.
  179. Chen CH, Huang MC, Kao CF, *et al.* Effects of adjunctive metformin on metabolic traits in nondiabetic clozapine-treated patients with schizophrenia and the effect of metformin discontinuation on body weight: a 24-week, randomized, double-blind, placebo-controlled study. *J Clin Psychiatry* 2013; 74: e424–30.
  180. Siskind D, Hahn M, Correll CU, *et al.* Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: a systematic review and individual participant data meta-analysis. *Diabetes Obes Metab* 2019; 21: 293–302.
  181. Afshar H, Roohafza H, Mousavi G, *et al.* Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial. *J Psychopharmacol* 2009; 23: 157–162.
  182. Dayabandara M, Hanwell R, Ratnatunga S, *et al.* Antipsychotic-associated weight gain: management strategies and impact on treatment adherence. *Neuropsychiatr Dis Treat* 2017; 13: 2231–2241.
  183. Ellinger LK, Ipema HJ and Stachnik JM. Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain. *Ann Pharmacother* 2010; 44: 668–679.
  184. Zhuo C, Xu Y, Liu S, *et al.* Topiramate and metformin are effective add-on treatments in controlling antipsychotic-induced weight gain: a systematic review and network meta-analysis. *Front Pharmacol* 2018; 9: 1393.
  185. Grover S, Sahoo S and Mahajan S. Clozapine-induced hypertension: a case report and review of literature. *Ind Psychiatry J* 2017; 26: 103–105.
  186. Yuen JWY, Kim DD, Procyshyn RM, *et al.* Clozapine-induced cardiovascular side effects and autonomic dysfunction: a systematic review. *Front Neurosci* 2018; 12: 203–203.
  187. Maher S, Cunningham A, O'Callaghan N, *et al.* Clozapine-induced hypersalivation: an estimate of prevalence, severity and impact on quality of life. *Ther Adv Psychopharmacol* 2016; 6: 178–184.
  188. Corrigan FM, MacDonald S and Reynolds GP. Clozapine-induced hypersalivation and the alpha 2 adrenoceptor. *Br J Psychiatry* 1995; 167: 412.
  189. Gupta S, Khastgir U, Croft M, *et al.* Management of clozapine-induced sialorrhoea. *BJpsych Advances* 2020; 26: 106–108.
  190. Citrome L, McEvoy JP and Saklad SR. Guide to the management of clozapine-related tolerability and safety concerns. *Clin Schizophr Relat Psychoses* 2016; 10: 163–177.
  191. Sockalingam S, Shammi C and Remington G. Clozapine-induced hypersalivation: a review of treatment strategies. *Can J Psychiatry* 2007; 52: 377–384.
  192. Kreinin A, Miodownik C, Sokolik S, *et al.* Amisulpride versus moclobemide in treatment of clozapine-induced hypersalivation. *World J Biol Psychiatry* 2011; 12: 620–626.
  193. Praharaj SK, Arora M and Gandotra S. Clozapine-induced sialorrhea: pathophysiology and management strategies. *Psychopharmacology* 2006; 185: 265–273.
  194. Bird AM, Smith TL and Walton AE. Current treatment strategies for clozapine-induced sialorrhea. *Ann Pharmacother* 2011; 45: 667–675.
  195. Verma R and Anand KS. Botulinum toxin: a novel therapy for clozapine-induced sialorrhoea. *Psychopharmacology* 2018; 235: 369–371.
  196. Jost WH, Bäumer T, Laskawi R, *et al.* Therapy of sialorrhea with botulinum neurotoxin. *Neurol Ther* 2019; 8: 273–288.
  197. Oliveira AF Filho, Silva GA and Almeida DM. Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review. *Einstein* 2016; 14: 431–434.
  198. Ruiz-Roca JA, Pons-Fuster E and Lopez-Jornet P. Effectiveness of the botulinum toxin for

- treating sialorrhea in patients with Parkinson's disease: a systematic review. *J Clin Med* 2019; 8: 317.
199. Caetano J and Delgado Alves J. Heart rate and cardiovascular protection. *Eur J Intern Med* 2015; 26: 217–222.
200. Cohen H, Loewenthal U, Matar M, *et al.* Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. *Br J Psychiatry* 2001; 179: 167–171.
201. Hindricks G, Potpara T, Dagres N, *et al.* 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur Heart J* 2021; 42: 373–498.
202. Brugada J, Katritsis DG, Arbelo E, *et al.* 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J* 2020; 41: 655–720.
203. Lally J, Brook J, Dixon T, *et al.* Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. *Ther Adv Psychopharmacol* 2014; 4: 117–122.
204. Stryjer R, Timinsky I, Reznik I, *et al.* Beta-adrenergic antagonists for the treatment of clozapine-induced sinus tachycardia: a retrospective study. *Clin Neuropharmacol* 2009; 32: 290–292.
205. Oke V, Schmidt F, Bhattarai B, *et al.* Unrecognized clozapine-related constipation leading to fatal intra-abdominal sepsis – a case report. *Int Med Case Rep J* 2015; 8: 189–192.
206. Shirazi A, Stubbs B, Gomez L, *et al.* Prevalence and predictors of clozapine-associated constipation: a systematic review and meta-analysis. *Int J Mol Sci* 2016; 17: 863.
207. Paquette IM, Varma M, Ternent C, *et al.* The American Society of Colon and Rectal Surgeons' clinical practice guideline for the evaluation and management of constipation. *Dis Colon Rectum* 2016; 59: 479–492.
208. Włodarczyk J, Waśniewska A, Fichna J, *et al.* Current overview on clinical management of chronic constipation. *J Clin Med* 2021; 10: 1738.
209. Chew ML, Mulsant BH, Pollock BG, *et al.* A model of anticholinergic activity of atypical antipsychotic medications. *Schizophr Res* 2006; 88: 63–72.
210. Lieberman JA III. Managing anticholinergic side effects. *Prim Care Companion J Clin Psychiatry* 2004; 6(Suppl. 2): 20–23.
211. DGNM. Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutsche Gesellschaft für Neurogastroenterologie & Motilität (DGNM), 2022, [https://register.awmf.org/assets/guidelines/021-019l\\_S2k\\_Chronische\\_Obstipation\\_2022-04\\_01.pdf](https://register.awmf.org/assets/guidelines/021-019l_S2k_Chronische_Obstipation_2022-04_01.pdf)
212. Taylor D, Barnes T and Young A. *The Maudsley prescribing guidelines in psychiatry*. Hoboken, NJ: Wiley-Blackwell, 2021.
213. Myles N, Myles H, Xia S, *et al.* Meta-analysis examining the epidemiology of clozapine-associated neutropenia. *Acta Psychiatr Scand* 2018; 138: 101–109.
214. Borrelli EP, Lee EY and Caffrey AR. Clozapine and hematologic adverse reactions: impact of the risk evaluation and mitigation strategy program. *Ment Health Clin* 2020; 10: 70–75.
215. Mijovic A and MacCabe JH. Clozapine-induced agranulocytosis. *Ann Hematol* 2020; 99: 2477–2482.
216. Dale DC. How I diagnose and treat neutropenia. *Curr Opin Hematol* 2016; 23: 1–4.
217. Nielsen J, Correll CU, Manu P, *et al.* Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? *J Clin Psychiatry* 2013; 74: 603–613; quiz 613.
218. Wiciński M and Węclewicz MM. Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring. *Curr Opin Hematol* 2018; 25: 22–28.
219. Oloyede E, Whiskey E, Casetta C, *et al.* Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study. *Lancet Psychiatry* 2022; 9: 636–644.
220. Sultan RS, Olsson M, Correll CU, *et al.* Evaluating the effect of the changes in FDA

- guidelines for clozapine monitoring. *J Clin Psychiatry* 2017; 78: e933–e939.
221. Silva E, Higgins M, Hammer B, *et al.* Clozapine rechallenge and initiation despite neutropenia – a practical, step-by-step guide. *BMC Psychiatry* 2020; 20: 279.
  222. Manu P, Sarvaiya N, Rogozia LM, *et al.* Benign ethnic neutropenia and clozapine use: a systematic review of the evidence and treatment recommendations. *J Clin Psychiatry* 2016; 77: e909–e916.
  223. Oloyede E, Dzahini O, Barnes N, *et al.* Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals. *BMC Psychiatry* 2021; 21: 502.
  224. Richardson N, Greenway SC and Bousman CA. Clozapine-induced myocarditis and patient outcomes after drug rechallenge following myocarditis: a systematic case review. *Psychiatry Res* 2021; 305: 114247.
  225. Palmblad J and Höglund P. Ethnic benign neutropenia: a phenomenon finds an explanation. *Pediatr Blood Cancer* 2018; 65: e27361.
  226. De Filippis R, Gaetano R, Schoretsanitis G, *et al.* Clozapine management in schizophrenia inpatients: a 5-year prospective observational study of its safety and tolerability profile. *Neuropsychiatr Dis Treat* 2021; 17: 2141–2150.
  227. Grover S, Shouan A, Chakrabarti S, *et al.* Haematological side effects associated with clozapine: a retrospective study from India. *Asian J Psychiatr* 2020; 48: 101906.
  228. Kate N, Grover S, Aggarwal M, *et al.* Clozapine associated thrombocytopenia. *J Pharmacol Pharmacother* 2013; 4: 149–151.
  229. Aneja J, Sharma N, Mahajan S, *et al.* Eosinophilia induced by clozapine: a report of two cases and review of the literature. *J Family Med Prim Care* 2015; 4: 127–129.
  230. De Filippis R, Soldevila-Matías P, De Fazio P, *et al.* Clozapine-related drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a systematic review. *Expert Rev Clin Pharmacol* 2020; 13: 875–883.
  231. Lally J, O'Connor N, Fullam S, *et al.* Rechallenge following clozapine-associated eosinophilia: a case report and literature review. *J Clin Psychopharmacol* 2019; 39: 504–506.
  232. McArdle PA, Siskind DJ, Kolur U, *et al.* Successful rechallenge with clozapine after treatment associated eosinophilia. *Australas Psychiatry* 2016; 24: 365–367.
  233. Tiihonen J and Paanila J. Eosinophilia associated with clozapine. *Lancet* 1992; 339: 488.
  234. Legge SE, Hamshire M, Hayes RD, *et al.* Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. *Schizophr Res* 2016; 174: 113–119.
  235. Kilian JG, Kerr K, Lawrence C, *et al.* Myocarditis and cardiomyopathy associated with clozapine. *Lancet* 1999; 354: 1841–1845.
  236. Layland JJ, Liew D and Prior DL. Clozapine-induced cardiotoxicity: a clinical update. *Med J Aust* 2009; 190: 190–192.
  237. Ronaldson KJ, Fitzgerald PB, Taylor AJ, *et al.* Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. *Schizophr Res* 2012; 141: 173–178.
  238. Beck K, McCutcheon R, Bloomfield MA, *et al.* The practical management of refractory schizophrenia – the Maudsley Treatment REview and Assessment Team service approach. *Acta Psychiatr Scand* 2014; 130: 427–438.
  239. Ronaldson KJ, Fitzgerald PB and McNeil JJ. Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis. *Aust N Z J Psychiatry* 2015; 49: 486–487.
  240. Curto M, Girardi N, Lionetto L, *et al.* Systematic review of clozapine cardiotoxicity. *Curr Psychiatry Rep* 2016; 18: 68.
  241. Ronaldson KJ, Fitzgerald PB, Taylor AJ, *et al.* A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. *Aust N Z J Psychiatry* 2011; 45: 458–465.
  242. Higgins JM, San C, Lagnado G, *et al.* Incidence and management of clozapine-induced myocarditis in a large tertiary hospital. *Can J Psychiatry* 2019; 64: 561–567.
  243. Shivakumar G, Thomas N, Sollychin M, *et al.* Protocol for clozapine rechallenge in a case of clozapine-induced myocarditis. *Can J Psychiatry* 2019; 65: 448–453.
  244. Caforio AL, Pankuweit S, Arbustini E, *et al.* Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. *Eur Heart J* 2013; 34: 2636–2648a, 2648a–2648d.

245. Kallergis EM, Goudis CA, Simantirakis EN, *et al.* Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. *Sci World J* 2012; 2012: 212178.
246. Merrill DB, Dec GW and Goff DC. Adverse cardiac effects associated with clozapine. *J Clin Psychopharmacol* 2005; 25: 32–41.
247. Chen Y, Guo X, Sun G, *et al.* Effect of serum electrolytes within normal ranges on QTc prolongation: a cross-sectional study in a Chinese rural general population. *BMC Cardiovasc Disord* 2018; 18: 175.
248. Bolu A, Akarsu S, Pan E, *et al.* Low-dose clozapine-induced seizure: a case report. *Clin Psychopharmacol Neurosci* 2017; 15: 190–193.
249. Pacia SV and Devinsky O. Clozapine-related seizures. Experience with 5,629 patients. *Neurology* 1994; 44: 2247–2249.
250. Williams AM and Park SH. Seizure associated with clozapine: incidence, etiology, and management. *CNS Drugs* 2015; 29: 101–111.
251. Rao NP, Sheth S and Varambally S. Lacosamide precipitated neutropenia in a patient with bipolar disorder and comorbid epilepsy. *Indian J Psychol Med* 2018; 40: 496–497.
252. Lin SK, Su SF and Pan CH. Higher plasma drug concentration in clozapine-treated schizophrenic patients with side effects of obsessive/compulsive symptoms. *Ther Drug Monit* 2006; 28: 303–307.
253. Schirmbeck F and Zink M. Clozapine-induced obsessive-compulsive symptoms in schizophrenia: a critical review. *Curr Neuropsychopharmacol* 2012; 10: 88–95.
254. Cohen BM, Keck PE, Satlin A, *et al.* Prevalence and severity of akathisia in patients on clozapine. *Biol Psychiatry* 1991; 29: 1215–1219.
255. Hirjak D, Kubera KM, Bienentreu S, *et al.* Antipsychotikaassoziierte motorische Symptome bei schizophrenen Psychosen – Teil 1. *Der Nervenarzt* 2019; 90: 1–11.
256. Poyurovsky M and Weizman A. Treatment of antipsychotic-induced akathisia: role of serotonin 5-HT(2a) receptor antagonists. *Drugs* 2020; 80: 871–882.
257. Kern DS and Lang AE. Acute akathisia. In: Friedman JH (ed.) *Medication-induced movement disorders*. Cambridge: Cambridge University Press, 2015, pp. 3–19.
258. Grover S and Sahoo S. Clozapine induced akathisia: a case report and review of the evidence. *Indian J Pharmacol* 2015; 47: 234–235.
259. Takeshima M, Ishikawa H, Kikuchi Y, *et al.* Successful management of clozapine-induced akathisia with gabapentin enacarbil: a case report. *Clin Psychopharmacol Neurosci* 2018; 16: 346–348.
260. Benkert O and Hippus H. *Kompendium der Psychiatrischen Pharmakotherapie*. Berlin: Springer, 2019.
261. Kuo CJ, Yang SY, Liao YT, *et al.* Second-generation antipsychotic medications and risk of pneumonia in schizophrenia. *Schizophr Bull* 2013; 39: 648–657.
262. Lam YWF. Pneumonia risk in patients receiving clozapine. *Brown Univ Psychopharm Update* 2021; 32: 2–3.
263. Schoretsanitis G, Ruan CJ, Rohde C, *et al.* An update on the complex relationship between clozapine and pneumonia. *Expert Rev Clin Pharmacol* 2021; 14: 145–149.
264. Hinkes R, Quesada TV, Currier MB, *et al.* Aspiration pneumonia possibly secondary to clozapine-induced sialorrhea. *J Clin Psychopharmacol* 1996; 16: 462–463.
265. Hung GC, Liu HC, Yang SY, *et al.* Antipsychotic reexposure and recurrent pneumonia in schizophrenia: a nested case-control study. *J Clin Psychiatry* 2016; 77: 60–66.
266. De Leon J, Ruan CJ, Verdoux H, *et al.* Clozapine is strongly associated with the risk of pneumonia and inflammation. *Gen Psychiatry* 2020; 33: e100183.
267. Bergemann N, Ehrig C, Diebold K, *et al.* Asymptomatic pancreatitis associated with clozapine. *Pharmacopsychiatry* 1999; 32: 78–80.
268. Lally J, Al Kalbani H, Krivoy A, *et al.* Hepatitis, interstitial nephritis, and pancreatitis in association with clozapine treatment: a systematic review of case series and reports. *J Clin Psychopharmacol* 2018; 38: 520–527.
269. Manu P, Sarpal D, Muir O, *et al.* When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. *Schizophr Res* 2012; 134: 180–186.
270. Dhillon N and Heun R. Nocturnal enuresis is an under-recognised side effect of clozapine: results of a systematic review. *Global Psychiatry* 2020; 2: 21–30.
271. Karagianis JL, Phillips LC, Hogan KP, *et al.* Clozapine-associated neuroleptic malignant syndrome: two new cases and a review of the literature. *Ann Pharmacother* 1999; 33: 623–630.

272. De Filippis R, Soldevila-Matias P, Guinart D, *et al.* Unravelling cases of clozapine-related Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) in patients reported otherwise: a systematic review. *J Psychopharmacol* 2021; 35: 1062–1073.
273. Flanagan RJ and Dunk L. Haematological toxicity of drugs used in psychiatry. *Hum Psychopharmacol* 2008; 23(Suppl. 1): 27–41.
274. Koller E, Schneider B, Bennett K, *et al.* Clozapine-associated diabetes. *Am J Med* 2001; 111: 716–723.
275. Das A, Minner R, Krain L, *et al.* Delirium on clozapine: a tale of friend turned foe – a case report. *Int J Psychiatry Med* 2021; 56: 446–458.
276. Stanilla JK, De Leon J and Simpson GM. Clozapine withdrawal resulting in delirium with psychosis: a report of three cases. *J Clin Psychiatry* 1997; 58: 252–255.
277. Agarwal P, Omoruyi A, Perai KG, *et al.* Neuroleptic malignant syndrome (NMS) on clozapine with a potential atypical interaction with paliperidone. *Case Rep Psychiatry* 2021; 2021: 5584104.
278. Young CR, Bowers MB Jr and Mazure CM. Management of the adverse effects of clozapine. *Schizophr Bull* 1998; 24: 381–390.
279. Rodriguez V, Hanley K, Arias AJ, *et al.* Successful clozapine rechallenge following recurrent clozapine-associated pancreatitis: a case report. *BMC Pharmacol Toxicol* 2020; 21: 35.
280. Spring JD, Goldstein BN, Buster M, *et al.* Physostigmine for facilitation of care in clozapine-associated anticholinergic delirium. *J Clin Psychopharmacol* 2022; 42: 329–331.
281. Idänpään-Heikkilä J, Alhava E, Olkinuora M, *et al.* Letter: clozapine and agranulocytosis. *Lancet* 1975; 306: 611.
282. Lustberg MB. Management of neutropenia in cancer patients. *Clin Adv Hematol Oncol* 2012; 10: 825–826.
283. Lorenzo-Villalba N, Alonso-Ortiz MB, Maouche Y, *et al.* Idiosyncratic drug-induced neutropenia and agranulocytosis in elderly patients. *J Clin Med* 2020; 9: 1808.
284. Sun C, Zhao L, Yuan Y, *et al.* Detection of drug safety signal of drug-induced neutropenia and agranulocytosis in all-aged patients using electronic medical records. *Pharmacoepidemiol Drug Saf.* Epub ahead of print 28 October 2022. DOI: 10.1002/pds.5559.
285. Sedhai YR, Lamichhane A and Gupta V. *Agranulocytosis*. Treasure Island, FL: StatPearls Publishing, 2022.
286. Taylor D, Shapland L, Laverick G, *et al.* Clozapine – a survey of patient perceptions. *Psychiatr Bull* 2000; 24: 450–452.
287. Silva E, Higgins M, Hammer B, *et al.* Clozapine re-challenge and initiation following neutropenia: a review and case series of 14 patients in a high-secure forensic hospital. *Ther Adv Psychopharmacol* 2021; 11.
288. Duggal HS and Singh I. Re: late-onset neutropenia with clozapine. *Can J Psychiatry* 2006; 51: 125; author reply 125–126.
289. Small JG, Weber MC, Klapper MH, *et al.* Rechallenge of late-onset neutropenia with clozapine. *J Clin Psychopharmacol* 2005; 25: 185–186.
290. Johannsen CF, Petersen TS, Nielsen J, *et al.* Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study. *Ther Adv Psychopharmacol* 2022; 12.
291. Taylor D, Vallianatou K, Whiskey E, *et al.* Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis. *Schizophrenia* 2022; 8: 21.
292. Hummer M, Kurz M, Barnas C, *et al.* Transient neutropenia induced by clozapine. *Psychopharmacol Bull* 1992; 28: 287–290.
293. Nooijen PM, Carvalho F and Flanagan RJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. *Hum Psychopharmacol* 2011; 26: 112–119.
294. Malik S, Lally J, Ajnakina O, *et al.* Sodium valproate and clozapine induced neutropenia: a case control study using register data. *Schizophr Res* 2018; 195: 267–273.
295. Meyer N, Gee S, Whiskey E, *et al.* Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis. *J Clin Psychiatry* 2015; 76: e1410–6.
296. Moga S, Teodorescu A, Ifteni P, *et al.* Clozapine and neutropenia in patients with schizophrenia and SARS-CoV-2 infection. *Neuropsychiatr Dis Treat* 2022; 18: 977–983.
297. Herold G. *Innere Medizin 2023* [Internal medicine]. Berlin; Boston, MA: De Gruyter, 2023.
298. Fenelon LE. Protective isolation: who needs it? *J Hosp Infect* 1995; 30(Suppl.): 218–222.

299. Schnell D, Azoulay E, Benoit D, *et al.* Management of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French Society of Anesthesia and Intensive Care (SFAR), the French Society of Hematology (SFH), the French Society for Hospital Hygiene (SF2H), and the French Infectious Diseases Society (SPILF). *Ann Intensive Care* 2016; 6: 90.
300. Silva E, Higgins M, Hammer B, *et al.* Clozapine rechallenge and initiation despite neutropenia – a practical, step-by-step guide. *BMC Psychiatry* 2020; 20: 279.
301. Lam YWF. Eosinophilia associated with clozapine therapy. *Brown Univ Psychopharm Update* 2021; 32: 2–2.
302. Roberts CE, Mortenson LY, Merrill DB, *et al.* Successful rechallenge with clozapine after eosinophilia. *Am J Psychiatry* 2011; 168: 1147–1151.
303. Tiihonen J, Tanskanen A, Bell JS, *et al.* Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland. *Lancet Psychiatry* 2022; 9: 353–362.
304. De Leon J, De Las Cuevas C, Sanz EJ, *et al.* Clozapine and the risk of haematological malignancies. *Lancet Psychiatry* 2022; 9: 537–538.
305. Schulte PF, Cohen D, Veerman SR, *et al.* Clozapine and the risk of haematological malignancies. *Lancet Psychiatry* 2022; 9: 538–539.
306. Van Der Horst MZ, Van Houwelingen F and Luykx JJ. Isolated nausea and vomiting as the cardinal presenting symptoms of clozapine-induced myocarditis: a case report. *BMC Psychiatry* 2020; 20: 568.
307. Lang UE, Willbring M, Von Golitschek R, *et al.* Clozapine-induced myocarditis after long-term treatment: case presentation and clinical perspectives. *J Psychopharmacol* 2008; 22: 576–580.
308. Tan LH, Suetani S, Clark S, *et al.* Late onset myocarditis with clozapine use. *Aust N Z J Psychiatry* 2015; 49: 295.
309. Bellissima BL, Tingle MD, Cicović A, *et al.* A systematic review of clozapine-induced myocarditis. *Int J Cardiol* 2018; 259: 122–129.
310. Segev A, Iqbal E, McDonagh TA, *et al.* Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy. *Br J Psychiatry* 2021; 219: 644–651.
311. Haas SJ, Hill R, Krum H, *et al.* Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. *Drug Saf* 2007; 30: 47–57.
312. Siskind D, Sidhu A, Cross J, *et al.* Systematic review and meta-analysis of rates of clozapine-associated myocarditis and cardiomyopathy. *Aust N Z J Psychiatry* 2020; 54: 467–481.
313. Ariyaratnam V, Shaikh N, Garber PJ, *et al.* Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: is there a role in the absence of electrocardiographic and echocardiographic abnormalities? *J Magn Reson Imaging* 2010; 31: 1473–1476.
314. Karatolios K, Pankuweit S and Maisch B. Diagnosis and treatment of myocarditis: the role of endomyocardial biopsy. *Curr Treat Options Cardiovasc Med* 2007; 9: 473–481.
315. Riggs AR and Cooper DM. Clozapine-induced myocarditis. *US Pharm* 2018; 43: HS2–HS7.
316. Reinders J, Parsonage W, Lange D, *et al.* Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. *Aust N Z J Psychiatry* 2004; 38: 915–922.
317. Cheng A, Ahmed M and Shuaib W. Intravenous immunoglobulin and methylprednisolone for clozapine-associated perimyocarditis. *Am J Ther* 2019; 26: e485–e486.
318. Ronaldson KJ, Fitzgerald PB, Taylor AJ, *et al.* Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. *Schizophr Res* 2011; 128: 161–165.
319. Abdel-Wahab BA and Metwally ME. Clozapine-induced cardiotoxicity: role of oxidative stress, tumour necrosis factor alpha and NF- $\kappa$ B. *Cardiovasc Toxicol* 2015; 15: 355–365.
320. Devarajan S, Kutcher SP and Dursun SM. Clozapine and sudden death. *Lancet* 2000; 355: 841; author reply 843.
321. Hägg S, Spigset O, Bate A, *et al.* Myocarditis related to clozapine treatment. *J Clin Psychopharmacol* 2001; 21: 382–388.
322. Pollmächer T, Schuld A, Kraus T, *et al.* [On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors].

- Fortschr Neurol Psychiatr* 2001; 69(Suppl. 2): S65–S74.
323. Wang JF, Min JY, Hampton TG, *et al.* Clozapine-induced myocarditis: role of catecholamines in a murine model. *Eur J Pharmacol* 2008; 592: 123–127.
  324. Jahołkowski P, Niewiadomska J, Wciórka J, *et al.* Clozapine-induced myocarditis during co-administration of valproate: a case report. *Psychiatr Pol* 2019; 53: 9971002.
  325. Arzuk E, Karakuş F and Orhan H. Bioactivation of clozapine by mitochondria of the murine heart: possible cause of cardiotoxicity. *Toxicology* 2021; 447: 152628.
  326. De Leon J, Rhee DW, Kondracke A, *et al.* Rapid titration and decreased clozapine clearance may help explain five cases of clozapine-induced myocarditis in a New York Hospital. *Psychosomatics* 2020; 61: 102–103.
  327. Every-Palmer S and Ellis PM. Clozapine-induced gastrointestinal hypomotility: a 22-year bi-national pharmacovigilance study of serious or fatal ‘slow gut’ reactions, and comparison with international drug safety advice. *CNS Drugs* 2017; 31: 699–709.
  328. Fowler JA. Clozapine-induced gastrointestinal hypomotility: more than just constipation. *Ment Health Clin* 2011; 1: 92–93.
  329. Palmer SE, McLean RM, Ellis PM, *et al.* Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. *J Clin Psychiatry* 2008; 69: 759–768.
  330. Handley SA, Every-Palmer S, Ismail A, *et al.* Clozapine-induced gastrointestinal hypomotility: presenting features and outcomes, UK pharmacovigilance reports, 1992–2017. *Br J Psychiatry* 2022; 220: 355–363.
  331. Every-Palmer S, Nowitz M, Stanley J, *et al.* Clozapine-treated patients have marked gastrointestinal hypomotility, the probable basis of life-threatening gastrointestinal complications: a cross sectional study. *EBioMedicine* 2016; 5: 125–134.
  332. Lamberti JS, Olson D, Crilly JF, *et al.* Prevalence of the metabolic syndrome among patients receiving clozapine. *Am J Psychiatry* 2006; 163: 1273–1276.
  333. Tso G, Kumar P, Jayasooriya T, *et al.* Metabolic monitoring and management among clozapine users. *Australas Psychiatry* 2016; 25: 48–52.
  334. Galletly CA. Premature death in schizophrenia: bridging the gap. *Lancet Psychiatry* 2017; 4: 263–265.
  335. Allison DB, Mackell JA and McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. *Psychiatr Serv* 2003; 54: 565–567.
  336. Mizock L. The double stigma of obesity and serious mental illnesses: promoting health and recovery. *Psychiatr Rehabil J* 2012; 35: 466–469.
  337. Kane JM, Kishimoto T and Correll CU. Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies. *World Psychiatry* 2013; 12: 216–226.
  338. Weiden PJ, Mackell JA and McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. *Schizophr Res* 2004; 66: 51–57.
  339. Bora E, Akdede BB and Alptekin K. The relationship between cognitive impairment in schizophrenia and metabolic syndrome: a systematic review and meta-analysis. *Psychol Med* 2017; 47: 1030–1040.
  340. Hagi K, Nosaka T, Dickinson D, *et al.* Association between cardiovascular risk factors and cognitive impairment in people with schizophrenia: a systematic review and meta-analysis. *JAMA Psychiatry* 2021; 78: 510–518.
  341. Moritz S, Silverstein SM, Dietrichkeit M, *et al.* Neurocognitive deficits in schizophrenia are likely to be less severe and less related to the disorder than previously thought. *World Psychiatry* 2020; 19: 254–255.
  342. Kelly AC, Sheitman BB, Hamer RM, *et al.* A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. *J Clin Psychopharmacol* 2014; 34: 441–445.
  343. Lund BC, Perry PJ, Brooks JM, *et al.* Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. *Arch Gen Psychiatry* 2001; 58: 1172–1176.
  344. Bai YM, Chen JY, Chen TT, *et al.* Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. *Schizophr Res* 2009; 108: 122–126.
  345. Henderson DC, Cagliero E, Gray C, *et al.* Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. *Am J Psychiatry* 2000; 157: 975–981.
  346. Lydon A, Vallely J, Tummon A, *et al.* Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a

- cross-sectional study. *Ir J Psychol Med* 2021; 38: 40–48.
347. Lappin JM, Wijaya M, Watkins A, *et al.* Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients. *Schizophr Res* 2018; 199: 367–373.
348. De Silva VA, Suraweera C, Ratnatunga SS, *et al.* Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis. *BMC Psychiatry* 2016; 16: 341.
349. Jiang W-L, Cai D-B, Yin F, *et al.* Adjunctive metformin for antipsychotic-induced dyslipidemia: a meta-analysis of randomized, double-blind, placebo-controlled trials. *Transl Psychiatry* 2020; 10: 117.
350. Wagner E, Kane JM, Correll CU, *et al.* Clozapine combination and augmentation strategies in patients with schizophrenia – recommendations from an international expert survey among the treatment response and resistance in psychosis (TRRIP) working group. *Schizophr Bull* 2020; 46: 1459–1470.
351. Petrides G, Malur C, Braga RJ, *et al.* Electroconvulsive therapy augmentation in clozapine-resistant schizophrenia: a prospective, randomized study. *Focus* 2019; 17: 76–82.
352. Wang C, Shi W, Xu J, *et al.* Outcomes and safety of concomitant topiramate or metformin for antipsychotics-induced obesity: a randomized controlled trial. *Ann Gen Psychiatry* 2020; 19: 68.
353. Correll CU, Newcomer JW, Silverman B, *et al.* Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: a 24-week phase 3 study. *Am J Psychiatry* 2020; 177: 1168–1178.
354. Rehan ST, Siddiqui AH, Khan Z, *et al.* Samidorphan/olanzapine combination therapy for schizophrenia: efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. *Ann Med Surg* 2022; 79: 104115.
355. American Diabetes Association. Introduction: standards of medical care in diabetes – 2022. *Diabetes Care* 2021; 45: S1–S2.
356. Taylor SI, Yazdi ZS and Beitelshes AL. Pharmacological treatment of hyperglycemia in type 2 diabetes. *J Clin Invest* 2021; 131: e142243.
357. Popli AP, Konicki PE, Jurjus GJ, *et al.* Clozapine and associated diabetes mellitus. *J Clin Psychiatry* 1997; 58: 108–111.
358. Wang PS, Glynn RJ, Ganz DA, *et al.* Clozapine use and risk of diabetes mellitus. *J Clin Psychopharmacol* 2002; 22: 236–243.
359. Quek YF, See YM, Yee JY, *et al.* Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia. *Asian J Psychiatry* 2022; 74: 103192.
360. Syed R, Au K, Cahill C, *et al.* Pharmacological interventions for clozapine-induced hypersalivation. *Cochrane Database Syst Rev* 2008; 3: CD005579.
361. Baldessarini RJ, Huston-Lyons D, Campbell A, *et al.* Do central antiadrenergic actions contribute to the atypical properties of clozapine? *Br J Psychiatry* 1992; 160(Suppl. 17): 12–16.
362. Zorn SH, Jones SB, Ward KM, *et al.* Clozapine is a potent and selective muscarinic M4 receptor agonist. *Eur J Pharmacol* 1994; 269: R1–R2.
363. Rehse M, Bartolovic M, Baum K, *et al.* Influence of antipsychotic and anticholinergic loads on cognitive functions in patients with schizophrenia. *Schizophr Res Treatment* 2016; 2016: 8213165.
364. Van Der Poorten T and De Hert M. The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: a systematic review. *Clin Case Rep* 2019; 7: 2108–2113.
365. Mustafa FA, Khan A, Burke J, *et al.* Sublingual atropine for the treatment of severe and hyoscine-resistant clozapine-induced sialorrhea. *Afr J Psychiatry* 2013; 16: 242.
366. Kahl KG, Hagenah J, Zapf S, *et al.* Botulinum toxin as an effective treatment of clozapine-induced hypersalivation. *Psychopharmacology* 2004; 173: 229–230.
367. Chen SY, Ravindran G, Zhang Q, *et al.* Treatment strategies for clozapine-induced sialorrhea: a systematic review and meta-analysis. *CNS Drugs* 2019; 33: 225–238.
368. Olfson M, Gerhard T, Huang C, *et al.* Premature mortality among adults with schizophrenia in the United States. *JAMA Psychiatry* 2015; 72: 1172–1181.
369. De Leon J. Reflections on the complex history of the concept of clozapine-induced inflammation during titration. *Psychiatr Danub* 2022; 34: 411–421.
370. De Leon J, Schoretsanitis G, Smith RL, *et al.* An international adult guideline for making clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and clozapine levels. *Pharmacopsychiatry* 2022; 55: 73–86.
371. Dean L and Kane M. Clozapine therapy and CYP genotype. In: Pratt VM, Scott SA,

- Pirmohamed M, *et al.* (eds) *Medical genetics summaries*. Bethesda, MD: National Center for Biotechnology Information, 2012.
372. Ruan CJ, Zang YN, Cheng YH, *et al.* Around 3% of 1,300 levels were elevated during infections in a retrospective review of 131 Beijing hospital in-patients with more than 24,000 days of clozapine treatment. *Psychother Psychosom* 2020; 89: 255–257.
  373. Nemani K, Li C, Olfson M, *et al.* Association of psychiatric disorders with mortality among patients with COVID-19. *JAMA Psychiatry* 2021; 78: 380–386.
  374. De Fazio P, Gaetano R, Caroleo M, *et al.* Rare and very rare adverse effects of clozapine. *Neuropsychiatr Dis Treat* 2015; 11: 1995–2003.
  375. Gürcan G, Hun Şenol Ş, Anıl Yağcıoğlu AE, *et al.* Common side effects and metabolic syndrome due to clozapine: relationship with the clinical variables and disability. *Türk Psikiyatri Derg* 2021; 32: 87–99.
  376. Iqbal E, Govind R, Romero A, *et al.* The side effect profile of clozapine in real world data of three large mental health hospitals. *PLoS ONE* 2020; 15: e0243437.
  377. Yada Y, Kitagawa K, Sakamoto S, *et al.* The relationship between plasma clozapine concentration and clinical outcome: a cross-sectional study. *Acta Psychiatr Scand* 2021; 143: 227–237.
  378. Fernandez-Egea E, Chen S, Jenkins C, *et al.* The effect of clozapine on self-reported duration of sleep and its interaction with 23 other medications: a 5-year naturalistic study. *J Clin Psychopharmacol* 2021; 41: 534–539.
  379. Kuzo N, Haen E, Ho DM, *et al.* Clozapine once- versus multiple-daily dosing: a two-center cross-sectional study, systematic review and meta-analysis. *Eur Arch Psychiatry Clin Neurosci*. Epub ahead of print 29 December 2022. DOI: 10.1007/s00406-022-01542-1.
  380. Freudenreich O, Henderson DC, Macklin EA, *et al.* Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. *J Clin Psychiatry* 2009; 70: 1674–1680.
  381. Dequardo JR. Modafinil-associated clozapine toxicity. *Am J Psychiatry* 2002; 159: 1243–1244.
  382. Davis MC, Fuller MA, Strauss ME, *et al.* Discontinuation of clozapine: a 15-year naturalistic retrospective study of 320 patients. *Acta Psychiatr Scand* 2014; 130: 30–39.
  383. Pai NB and Vella SC. Reason for clozapine cessation. *Acta Psychiatr Scand* 2012; 125: 39–44.
  384. Blackman G and Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. *Ther Adv Psychopharmacol* 2021; 11.
  385. Blackman G, Oloyede E, Horowitz M, *et al.* Reducing the risk of withdrawal symptoms and relapse following clozapine discontinuation – is it feasible to develop evidence-based guidelines? *Schizophr Bulletin* 2022; 48: 176–189.
  386. Shiovitz TM, Welke TL, Tigel PD, *et al.* Cholinergic rebound and rapid onset psychosis following abrupt clozapine withdrawal. *Schizophr Bull* 1996; 22: 591–595.
  387. Stevenson E, Schembri F, Green DM, *et al.* Serotonin syndrome associated with clozapine withdrawal. *JAMA Neurology* 2013; 70: 1054–1055.
  388. Galova A, Berney P, Desmeules J, *et al.* A case report of cholinergic rebound syndrome following abrupt low-dose clozapine discontinuation in a patient with type I bipolar affective disorder. *BMC Psychiatry* 2019; 19: 73.
  389. Luykx JJ, Stam N, Tanskanen A, *et al.* In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients with schizophrenia who discontinue clozapine. *Br J Psychiatry* 2020; 217: 498–505.
  390. Stam N, Taipale H, Tanskanen A, *et al.* Persistence of antipsychotic use after clozapine discontinuation: a real-world study across antipsychotics. *Clin Transl Sci* 2020; 13: 1170–1177.
  391. Keks N, Schwartz D and Hope J. Stopping and switching antipsychotic drugs. *Aust Prescr* 2019; 42: 152–157.
  392. Leucht S, Cipriani A, Spineli L, *et al.* Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. *Lancet* 2013; 382: 951–962.
  393. Masuda T, Misawa F, Takase M, *et al.* Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies. *JAMA Psychiatry* 2019; 76: 1052–1062.
  394. Krivoy A, Malka L, Fischel T, *et al.* Predictors of clozapine discontinuation in patients with schizophrenia. *Int Clin Psychopharmacol* 2011; 26: 311–315.
  395. Miura G, Tanaka K, Kemuriyama T, *et al.* Clinical outcomes after clozapine

- discontinuation in patients with schizophrenia: a systematic review. *Pharmacopsychiatry* 2022; 55: 181–192.
396. Mustafa FA, Burke JG, Abukmeil SS, *et al.* ‘Schizophrenia past clozapine’: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. *Pharmacopsychiatry* 2015; 48: 11–14.
397. Chouinard G, Samaha AN, Chouinard VA, *et al.* Antipsychotic-induced dopamine supersensitivity psychosis: pharmacology, criteria, and therapy. *Psychother Psychosom* 2017; 86: 189–219.
398. Cosci F and Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. *Psychother Psychosom* 2020; 89: 283–306.
399. Diamond BI and Borison RL. Basic and clinical studies of neuroleptic-induced supersensitivity psychosis and dyskinesia. *Psychopharmacol Bull* 1986; 22: 900–905.
400. Moncrieff J. Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. *Acta Psychiatr Scand* 2006; 114: 3–13.
401. Viguera AC, Baldessarini RJ, Hegarty JD, *et al.* Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. *Arch Gen Psychiatry* 1997; 54: 49–55.
402. Lander M, Bastiampillai T and Sareen J. Review of withdrawal catatonia: what does this reveal about clozapine? *Transl Psychiatry* 2018; 8: 139.
403. Hawkins JM, Archer KJ, Strakowski SM, *et al.* Somatic treatment of catatonia. *Int J Psychiatry Med* 1995; 25: 345–369.
404. Sienaert P, Dhossche DM, Vancampfort D, *et al.* A clinical review of the treatment of catatonia. *Front Psychiatry* 2014; 5: 181.
405. Sinclair DJM, Zhao S, Qi F, *et al.* Electroconvulsive therapy for treatment-resistant schizophrenia. *Cochrane Database Syst Rev* 2019; 3: CD011847.
406. Shore D, Matthews S, Cott J, *et al.* Clinical implications of clozapine discontinuation: report of an NIMH workshop. *Schizophr Bull* 1995; 21: 333–338.
407. Manu P, Lapitskaya Y, Shaikh A, *et al.* Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases. *Am J Ther* 2018; 25: e218–e223.
408. Bowers P, Rosenkrantz B, Palanci J, *et al.* A slow, cautious, and successful clozapine rechallenge after myocarditis. *Prim Care Companion CNS Disord* 2022; 24: 21cr02976.
409. Hosseini SA, Skrzypczak B, Yasaei R, *et al.* Successful clozapine re-challenge after suspected clozapine-induced myocarditis. *Am J Case Rep* 2020; 21: e926507-1–e926507-6.
410. Danilewitz M, Rafizadeh R and Bousman CA. Successful clozapine rechallenge after suspected clozapine-associated myocarditis: a case report. *J Clin Psychopharmacol* 2021; 41: 218–220.
411. Prokopez CR, Armesto AR, Gil Aguer MF, *et al.* Clozapine rechallenge after neutropenia or leucopenia. *J Clin Psychopharmacol* 2016; 36: 377–380.
412. Boazak M, Goldsmith DR and Cotes RO. Mask off? Lithium augmentation for clozapine rechallenge after neutropenia or agranulocytosis: discontinuation might be risky. *Prim Care Companion CNS Disord* 2018; 20: 18l02282.
413. Martina AC, Ee JS and Lamberti JS. A case of clozapine induced agranulocytosis 25 years after starting treatment: effective use of lithium for augmentation in rechallenge. *Schizophr Res* 2019; 210: 308–309.
414. Brunoni AR, Kobuti Ferreira LR, Gallucci-Neto J, *et al.* Lithium as a treatment of clozapine-induced neutropenia: a case report. *Prog Neuropsychopharmacol Biol Psychiatry* 2008; 32: 2006–2007.
415. Kutscher EC, Robbins GP, Kennedy WK, *et al.* Clozapine-induced leukopenia successfully treated with lithium. *Am J Health Syst Pharm* 2007; 64: 2027–2031.
416. Whiskey E and Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. *CNS Drugs* 2007; 21: 25–35.
417. Bender S, Linka T, Wolstein J, *et al.* Safety and efficacy of combined clozapine-lithium pharmacotherapy. *Int J Neuropsychopharmacol* 2004; 7: 59–63.
418. Rachamalla V, Haq A, Song MM, *et al.* Clozapine-induced microseizures, orofacial dyskinesia, and speech dysfluency in an adolescent with treatment resistant early onset schizophrenia on concurrent lithium therapy. *Case Rep Psychiatry* 2017; 2017: 7359095.
419. Béchard L, Corbeil O, Plante M, *et al.* Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: a Quebec case series. *J Psychopharmacol* 2021; 35: 1152–1157.
420. Shuman M, Moss L and Dilich A. Never say never: successful clozapine rechallenge after

- multiple episodes of neutropenia. *Focus* 2021; 19: 66–70.
421. Myles N, Myles H, Clark SR, *et al.* Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: a systematic review of the literature and clinical recommendations. *Aust N Z J Psychiatry* 2017; 51: 980–989.
  422. Shaw BE, Confer DL, Hwang W, *et al.* A review of the genetic and long-term effects of G-CSF injections in healthy donors: a reassuring lack of evidence for the development of haematological malignancies. *Bone Marrow Transplant* 2015; 50: 334–340.
  423. Dale DC, Bolyard A, Marrero T, *et al.* Long-term effects of G-CSF therapy in cyclic neutropenia. *N Engl J Med* 2017; 377: 2290–2292.
  424. Freeman GM, Martin BA and Hu RJ. G-CSF dosing to prevent recurrent clozapine-induced agranulocytosis. *Am J Psychiatry* 2016; 173: 643–643.
  425. Hägg S, Rosenius S and Spigset O. Long-term combination treatment with clozapine and filgrastim in patients with clozapine-induced agranulocytosis. *Int Clin Psychopharmacol* 2003; 18: 173–174.
  426. Johannesen S, Khomenko A, Baldaranov D, *et al.* Safety, tolerability and monitoring of long-term G-CSF compassionate use in ALS patients (P3.181). *Neurology* 2016; 86: P3181.
  427. Ronaldson KJ, Fitzgerald PB, Taylor AJ, *et al.* Observations from 8 cases of clozapine rechallenge after development of myocarditis. *J Clin Psychiatry* 2012; 73: 252–254.
  428. Toni-Uebari TK and Rees J. Successful rechallenge with clozapine following ‘red alert’. *BMJ Case Rep* 2013; 2013: bcr2012007172.
  429. Cook SC, Ferguson BA, Cotes RO, *et al.* Clozapine-induced myocarditis: prevention and considerations in rechallenge. *Psychosomatics* 2015; 56: 685–690.
  430. Knoph KN, Morgan RJ 3rd, Palmer BA, *et al.* Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. *Schizophr Res* 2018; 199: 17–30.
  431. Noël MC, Powell V, Burton L, *et al.* Clozapine-related myocarditis and rechallenge: a case series and clinical review. *J Clin Psychopharmacol* 2019; 39: 380–385.
  432. Nguyen B, Du C, Bastiampillai T, *et al.* Successful clozapine re-challenge following myocarditis. *Australas Psychiatry* 2017; 25: 385–386.
  433. Beex-Oosterhuis MM, Samb A, Heerdink ER, *et al.* Safety of clozapine use during pregnancy: analysis of international pharmacovigilance data. *Pharmacoevidenc Drug Saf* 2020; 29: 725–735.
  434. Beex-Oosterhuis MM, Van Gool AR, Heerdink ER, *et al.* Clozapine treatment during pregnancy and the postpartum period: a systematic literature review. *J Clin Psychiatry* 2021; 83: 21r13952.
  435. Heinonen E, Forsberg L, Nörby U, *et al.* Antipsychotic use during pregnancy and risk for gestational diabetes: a national register-based cohort study in Sweden. *CNS Drugs* 2022; 36: 529–539.
  436. Mehta TM and Van Lieshout RJ. A review of the safety of clozapine during pregnancy and lactation. *Arch Womens Ment Health* 2017; 20: 1–9.
  437. Tracy TS, Venkataramanan R, Glover DD, *et al.* Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. *Am J Obstet Gynecol* 2005; 192: 633–639.
  438. Imaz ML, Oriolo G, Torra M, *et al.* Clozapine use during pregnancy and lactation: a case-series report. *Front Pharmacol* 2018; 9: 264.
  439. Uygur ÖF and Uygur H. Neurodevelopmental and growth follow-up of the baby exposed to antipsychotics during pregnancy and lactation: a case report. *Psychiatr Clin Psychopharmacol* 2019; 29: 744–747.
  440. Duran A, Ugur MM, Turan S, *et al.* Clozapine use in two women with schizophrenia during pregnancy. *J Psychopharmacol* 2008; 22: 111–113.
  441. Hatters Friedman S, Moller-Olsen C, Prakash C, *et al.* Atypical antipsychotic use and outcomes in an urban maternal mental health service. *Int J Psychiatry Med* 2016; 51: 521–533.
  442. Sreeraj VS and Venkatasubramanian G. Safety of clozapine in a woman with triplet pregnancy: a case report. *Asian J Psychiatr* 2016; 22: 67–68.
  443. Law A and Croucher M. Prescribing trends and safety of clozapine in an older persons mental health population. *Int Psychogeriatr* 2019; 31: 1823–1829.
  444. Mukku SSR, Sivakumar PT and Varghese M. Clozapine use in geriatric patients – challenges. *Asian J Psychiatr* 2018; 33: 63–67.
  445. Alvir JM, Lieberman JA, Safferman AZ, *et al.* Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. *N Engl J Med* 1993; 329: 162–167.

446. Gareri P, De Fazio P, Russo E, *et al.* The safety of clozapine in the elderly. *Expert Opin Drug Saf* 2008; 7: 525–538.
447. Herst L and Powell G. Is clozapine safe in the elderly? *Aust N Z J Psychiatry* 1997; 31: 411–417.
448. Fabrazzo M, La Pia S, Monteleone P, *et al.* Is the time course of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. *Neuropsychopharmacology* 2002; 27: 1050–1055.
449. Kappel DB, Legge SE, Hubbard L, *et al.* Genomic stratification of clozapine prescription patterns using schizophrenia polygenic scores. *Biol Psychiatry* 2023; 93: 149–156.
450. Morrison AP, Pyle M, Gumley A, *et al.* Cognitive behavioural therapy in clozapine-resistant schizophrenia (FOCUS): an assessor-blinded, randomised controlled trial. *Lancet Psychiatry* 2018; 5: 633–643.
451. Van Der Zalm Y, Foldager L, Termorshuizen F, *et al.* Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study. *Acta Psychiatr Scand* 2021; 143: 216–226.
452. Lähteenvuo M, Batalla A, Luykx J, *et al.* Morbidity and mortality in schizophrenia with comorbid substance use disorders in Finland and Sweden. *Eur Psychiatry* 2021; 64: S237–S238.
453. Solmi M, Tiihonen J, Lähteenvuo M, *et al.* Antipsychotics use is associated with greater adherence to cardiometabolic medications in patients with schizophrenia: results from a nationwide, within-subject design study. *Schizophr Bull* 2022; 48: 166–175.
454. Hjorthøj C, Stürup AE, McGrath JJ, *et al.* Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. *Lancet Psychiatry* 2017; 4: 295–301.
455. Tanskanen A, Tiihonen J and Taipale H. Mortality in schizophrenia: 30-year nationwide follow-up study. *Acta Psychiatr Scand* 2018; 138: 492–499.
456. Vermeulen JM, Van Rooijen G, Van De Kerkhof MPJ, *et al.* Clozapine and long-term mortality risk in patients with schizophrenia: a systematic review and meta-analysis of studies lasting 1.1–12.5 years. *Schizophr Bull* 2019; 45: 315–329.
457. Farooq S and Taylor M. Clozapine: dangerous orphan or neglected friend? *Br J Psychiatry* 2011; 198: 247–249.
458. Till A and Silva E. A case report of the successful administration of clozapine in the face of myocardial infarction, pulmonary embolism and hyperlipidaemia resulting in the termination of long-term seclusion. *BMC Psychiatry* 2019; 19: 37.
459. Ochi S, Tagata H, Hasegawa N, *et al.* Clozapine treatment is associated with higher prescription rate of antipsychotic monotherapy and lower prescription rate of other concomitant psychotropics: a real-world nationwide study. *Int J Neuropsychopharmacol* 2022; 25: 818–826.
460. Hodge K and Jespersen S. Side-effects and treatment with clozapine: a comparison between the views of consumers and their clinicians. *Int J Ment Health Nurs* 2008; 17: 2–8.